CINXE.COM

<!DOCTYPE html> <html xmlns="http://www.w3.org/1999/xhtml" xmlns:dc="http://purl.org/dc/terms/" xmlns:doi="http://dx.doi.org/" lang="en" xml:lang="en" itemscope itemtype="http://schema.org/Article" class="no-js"> <head prefix="og: http://ogp.me/ns#"> <link rel="stylesheet" href="/resource/css/screen.css?799fe1743e1756fc85e62c15a170e1b9"/>   <link rel="stylesheet" type="text/css" href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,600"> <link media="print" rel="stylesheet" type="text/css" href="/resource/css/print.css"/> <script type="text/javascript"> var siteUrlPrefix = "/plosone/"; </script> <script src="/resource/js/vendor/modernizr-v2.7.1.js" type="text/javascript"></script> <script src="/resource/js/vendor/detectizr.min.js" type="text/javascript"></script> <link rel="shortcut icon" href="/resource/img/favicon.ico" type="image/x-icon"/> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> <link rel="canonical" href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026005" /> <meta name="description" content="Background The emergence of artemisinin-resistant P. falciparum malaria in South-East Asia highlights the need for continued global surveillance of the efficacy of artemisinin-based combination therapies. Methods On the Kenyan coast we studied the treatment responses in 474 children 6–59 months old with uncomplicated P. falciparum malaria in a randomized controlled trial of dihydroartemisinin-piperaquine vs. artemether-lumefantrine from 2005 to 2008. (ISRCTN88705995) Results The proportion of patients with residual parasitemia on day 1 rose from 55% in 2005–2006 to 87% in 2007–2008 (odds ratio, 5.4, 95%CI, 2.7–11.1; P<0.001) and from 81% to 95% (OR, 4.1, 95%CI, 1.7–9.9; P = 0.002) in the DHA-PPQ and AM-LM groups, respectively. In parallel, Kaplan-Meier estimated risks of apparent recrudescent infection by day 84 increased from 7% to 14% (P = 0.1) and from 6% to 15% (P = 0.05) with DHA-PPQ and AM-LM, respectively. Coinciding with decreasing transmission in the study area, clinical tolerance to parasitemia (defined as absence of fever) declined between 2005–2006 and 2007–2008 (OR body temperature >37.5°C, 2.8, 1.9–4.1; P<0.001). Neither in vitro sensitivity of parasites to DHA nor levels of antibodies against parasite extract accounted for parasite clearance rates or changes thereof. Conclusions The significant, albeit small, decline through time of parasitological response rates to treatment with ACTs may be due to the emergence of parasites with reduced drug sensitivity, to the coincident reduction in population-level clinical immunity, or both. Maintaining the efficacy of artemisinin-based therapy in Africa would benefit from a better understanding of the mechanisms underlying reduced parasite clearance rates. Trial Registration Controlled-Trials.com ISRCTN88705995" /> <meta name="citation_abstract" content="Background The emergence of artemisinin-resistant P. falciparum malaria in South-East Asia highlights the need for continued global surveillance of the efficacy of artemisinin-based combination therapies. Methods On the Kenyan coast we studied the treatment responses in 474 children 6–59 months old with uncomplicated P. falciparum malaria in a randomized controlled trial of dihydroartemisinin-piperaquine vs. artemether-lumefantrine from 2005 to 2008. (ISRCTN88705995) Results The proportion of patients with residual parasitemia on day 1 rose from 55% in 2005–2006 to 87% in 2007–2008 (odds ratio, 5.4, 95%CI, 2.7–11.1; P<0.001) and from 81% to 95% (OR, 4.1, 95%CI, 1.7–9.9; P = 0.002) in the DHA-PPQ and AM-LM groups, respectively. In parallel, Kaplan-Meier estimated risks of apparent recrudescent infection by day 84 increased from 7% to 14% (P = 0.1) and from 6% to 15% (P = 0.05) with DHA-PPQ and AM-LM, respectively. Coinciding with decreasing transmission in the study area, clinical tolerance to parasitemia (defined as absence of fever) declined between 2005–2006 and 2007–2008 (OR body temperature >37.5°C, 2.8, 1.9–4.1; P<0.001). Neither in vitro sensitivity of parasites to DHA nor levels of antibodies against parasite extract accounted for parasite clearance rates or changes thereof. Conclusions The significant, albeit small, decline through time of parasitological response rates to treatment with ACTs may be due to the emergence of parasites with reduced drug sensitivity, to the coincident reduction in population-level clinical immunity, or both. Maintaining the efficacy of artemisinin-based therapy in Africa would benefit from a better understanding of the mechanisms underlying reduced parasite clearance rates. Trial Registration Controlled-Trials.com ISRCTN88705995"> <meta name="keywords" content="Malarial parasites,Parasitic diseases,Malaria,Parasitemia,Medical risk factors,Immunity,Plasmodium,Artemisinin" /> <meta name="citation_doi" content="10.1371/journal.pone.0026005"/> <meta name="citation_author" content="Steffen Borrmann"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author_institution" content="Heidelberg University School of Medicine, Dept. of Infectious Diseases, Heidelberg, Germany"/> <meta name="citation_author" content="Philip Sasi"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author_institution" content="Department of Clinical Pharmacology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania"/> <meta name="citation_author" content="Leah Mwai"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author" content="Mahfudh Bashraheil"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author" content="Ahmed Abdallah"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author" content="Steven Muriithi"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author" content="Henrike Frühauf"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author_institution" content="Heidelberg University School of Medicine, Dept. of Infectious Diseases, Heidelberg, Germany"/> <meta name="citation_author" content="Barbara Schaub"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author_institution" content="Heidelberg University School of Medicine, Dept. of Infectious Diseases, Heidelberg, Germany"/> <meta name="citation_author" content="Johannes Pfeil"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author_institution" content="Heidelberg University School of Medicine, Dept. of Infectious Diseases, Heidelberg, Germany"/> <meta name="citation_author" content="Judy Peshu"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author" content="Warunee Hanpithakpong"/> <meta name="citation_author_institution" content="Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"/> <meta name="citation_author" content="Anja Rippert"/> <meta name="citation_author_institution" content="Heidelberg University School of Medicine, Dept. of Infectious Diseases, Heidelberg, Germany"/> <meta name="citation_author" content="Elizabeth Juma"/> <meta name="citation_author_institution" content="Division of Malaria Control, Ministry of Health, Nairobi, Kenya"/> <meta name="citation_author" content="Benjamin Tsofa"/> <meta name="citation_author_institution" content="District Office, Ministry of Health, Kilifi, Kenya"/> <meta name="citation_author" content="Moses Mosobo"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author" content="Brett Lowe"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author" content="Faith Osier"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author" content="Greg Fegan"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author" content="Niklas Lindegårdh"/> <meta name="citation_author_institution" content="Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"/> <meta name="citation_author" content="Alexis Nzila"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author" content="Norbert Peshu"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author" content="Margaret Mackinnon"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author_institution" content="Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, CCVTM, Oxford, United Kingdom"/> <meta name="citation_author" content="Kevin Marsh"/> <meta name="citation_author_institution" content="Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya"/> <meta name="citation_author_institution" content="Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, CCVTM, Oxford, United Kingdom"/> <meta name="citation_title" content="Declining Responsiveness of Plasmodium falciparum Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast"/> <meta itemprop="name" content="Declining Responsiveness of Plasmodium falciparum Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast"/> <meta name="citation_journal_title" content="PLOS ONE"/> <meta name="citation_journal_abbrev" content="PLOS ONE"/> <meta name="citation_date" content="Nov 10, 2011"/> <meta name="citation_firstpage" content="e26005"/> <meta name="citation_issue" content="11"/> <meta name="citation_volume" content="6"/> <meta name="citation_issn" content="1932-6203"/> <meta name="citation_publisher" content="Public Library of Science"/> <meta name="citation_pdf_url" content="https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0026005&type=printable"> <meta name="citation_article_type" content="Research Article"> <meta name="dc.identifier" content="10.1371/journal.pone.0026005" /> <meta name="twitter:card" content="summary" /> <meta name="twitter:site" content="plosone"/> <meta name="twitter:title" content="Declining Responsiveness of Plasmodium falciparum Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast" /> <meta property="twitter:description" content="Background The emergence of artemisinin-resistant P. falciparum malaria in South-East Asia highlights the need for continued global surveillance of the efficacy of artemisinin-based combination therapies. Methods On the Kenyan coast we studied the treatment responses in 474 children 6–59 months old with uncomplicated P. falciparum malaria in a randomized controlled trial of dihydroartemisinin-piperaquine vs. artemether-lumefantrine from 2005 to 2008. (ISRCTN88705995) Results The proportion of patients with residual parasitemia on day 1 rose from 55% in 2005–2006 to 87% in 2007–2008 (odds ratio, 5.4, 95%CI, 2.7–11.1; P<0.001) and from 81% to 95% (OR, 4.1, 95%CI, 1.7–9.9; P = 0.002) in the DHA-PPQ and AM-LM groups, respectively. In parallel, Kaplan-Meier estimated risks of apparent recrudescent infection by day 84 increased from 7% to 14% (P = 0.1) and from 6% to 15% (P = 0.05) with DHA-PPQ and AM-LM, respectively. Coinciding with decreasing transmission in the study area, clinical tolerance to parasitemia (defined as absence of fever) declined between 2005–2006 and 2007–2008 (OR body temperature >37.5°C, 2.8, 1.9–4.1; P<0.001). Neither in vitro sensitivity of parasites to DHA nor levels of antibodies against parasite extract accounted for parasite clearance rates or changes thereof. Conclusions The significant, albeit small, decline through time of parasitological response rates to treatment with ACTs may be due to the emergence of parasites with reduced drug sensitivity, to the coincident reduction in population-level clinical immunity, or both. Maintaining the efficacy of artemisinin-based therapy in Africa would benefit from a better understanding of the mechanisms underlying reduced parasite clearance rates. Trial Registration Controlled-Trials.com ISRCTN88705995" /> <meta property="twitter:image" content="https://journals.plos.org/plosone/article/figure/image?id=10.1371/journal.pone.0026005.g003&size=inline" /> <meta property="og:type" content="article" /> <meta property="og:url" content="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026005"/> <meta property="og:title" content="Declining Responsiveness of Plasmodium falciparum Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast"/> <meta property="og:description" content="Background The emergence of artemisinin-resistant P. falciparum malaria in South-East Asia highlights the need for continued global surveillance of the efficacy of artemisinin-based combination therapies. Methods On the Kenyan coast we studied the treatment responses in 474 children 6–59 months old with uncomplicated P. falciparum malaria in a randomized controlled trial of dihydroartemisinin-piperaquine vs. artemether-lumefantrine from 2005 to 2008. (ISRCTN88705995) Results The proportion of patients with residual parasitemia on day 1 rose from 55% in 2005–2006 to 87% in 2007–2008 (odds ratio, 5.4, 95%CI, 2.7–11.1; P<0.001) and from 81% to 95% (OR, 4.1, 95%CI, 1.7–9.9; P = 0.002) in the DHA-PPQ and AM-LM groups, respectively. In parallel, Kaplan-Meier estimated risks of apparent recrudescent infection by day 84 increased from 7% to 14% (P = 0.1) and from 6% to 15% (P = 0.05) with DHA-PPQ and AM-LM, respectively. Coinciding with decreasing transmission in the study area, clinical tolerance to parasitemia (defined as absence of fever) declined between 2005–2006 and 2007–2008 (OR body temperature >37.5°C, 2.8, 1.9–4.1; P<0.001). Neither in vitro sensitivity of parasites to DHA nor levels of antibodies against parasite extract accounted for parasite clearance rates or changes thereof. Conclusions The significant, albeit small, decline through time of parasitological response rates to treatment with ACTs may be due to the emergence of parasites with reduced drug sensitivity, to the coincident reduction in population-level clinical immunity, or both. Maintaining the efficacy of artemisinin-based therapy in Africa would benefit from a better understanding of the mechanisms underlying reduced parasite clearance rates. Trial Registration Controlled-Trials.com ISRCTN88705995"/> <meta property="og:image" content="https://journals.plos.org/plosone/article/figure/image?id=10.1371/journal.pone.0026005.g003&size=inline"/> <meta name="citation_reference" content="citation_title=Impact of chloroquine resistance on malaria mortality.;citation_author=JF Trape;citation_author=G Pison;citation_author=MP Preziosi;citation_author=C Enel;citation_author=A Desgrees du Lou;citation_journal_title=C R Acad Sci III;citation_volume=321;citation_number=321;citation_first_page=689;citation_last_page=697;citation_publication_date=1998;"/> <meta name="citation_reference" content="citation_title=Effectiveness of antimalarial drugs.;citation_author=JK Baird;citation_journal_title=N Engl J Med;citation_volume=352;citation_number=352;citation_first_page=1565;citation_last_page=1577;citation_publication_date=2005;"/> <meta name="citation_reference" content="citation_title=Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy.;citation_author=EL Korenromp;citation_author=BG Williams;citation_author=E Gouws;citation_author=C Dye;citation_author=RW Snow;citation_journal_title=Lancet Infect Dis;citation_volume=3;citation_number=3;citation_first_page=349;citation_last_page=358;citation_publication_date=2003;"/> <meta name="citation_reference" content="citation_title=Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar.;citation_author=A Bhattarai;citation_author=AS Ali;citation_author=SP Kachur;citation_author=A Martensson;citation_author=AK Abbas;citation_journal_title=PLoS Med;citation_volume=4;citation_number=4;citation_first_page=e309;citation_publication_date=2007;"/> <meta name="citation_reference" content="citation_title=Effect of Artemether-Lumefantrine Policy and Improved Vector Control on Malaria Burden in KwaZulu-Natal, South Africa.;citation_author=KI Barnes;citation_author=DN Durrheim;citation_author=F Little;citation_author=A Jackson;citation_author=U Mehta;citation_journal_title=PLoS Med;citation_volume=2;citation_number=2;citation_first_page=e330;citation_publication_date=2005;"/> <meta name="citation_reference" content="citation_title=Artemisinin resistance in Plasmodium falciparum malaria.;citation_author=AM Dondorp;citation_author=F Nosten;citation_author=P Yi;citation_author=D Das;citation_author=AP Phyo;citation_journal_title=N Engl J Med;citation_volume=361;citation_number=361;citation_first_page=455;citation_last_page=467;citation_publication_date=2009;"/> <meta name="citation_reference" content="citation_title=Evidence of artemisinin-resistant malaria in western Cambodia.;citation_author=H Noedl;citation_author=Y Se;citation_author=K Schaecher;citation_author=BL Smith;citation_author=D Socheat;citation_journal_title=N Engl J Med;citation_volume=359;citation_number=359;citation_first_page=2619;citation_last_page=2620;citation_publication_date=2008;"/> <meta name="citation_reference" content="citation_title=Artemisinin-resistant malaria in Asia.;citation_author=H Noedl;citation_author=D Socheat;citation_author=W Satimai;citation_journal_title=N Engl J Med;citation_volume=361;citation_number=361;citation_first_page=540;citation_last_page=541;citation_publication_date=2009;"/> <meta name="citation_reference" content="citation_title=Artemisinin resistance: current status and scenarios for containment.;citation_author=AM Dondorp;citation_author=S Yeung;citation_author=L White;citation_author=C Nguon;citation_author=NP Day;citation_journal_title=Nat Rev Microbiol;citation_volume=8;citation_number=8;citation_first_page=272;citation_last_page=280;citation_publication_date=2010;"/> <meta name="citation_reference" content="citation_title=In vivo and in vitro efficacy of amodiaquine against Plasmodium falciparum in an area of continued use of 4-aminoquinolines in East Africa.;citation_author=P Sasi;citation_author=A Abdulrahaman;citation_author=L Mwai;citation_author=S Muriithi;citation_author=J Straimer;citation_journal_title=J Infect Dis;citation_volume=199;citation_number=199;citation_first_page=1575;citation_last_page=1582;citation_publication_date=2009;"/> <meta name="citation_reference" content="citation_title=Defining clinical malaria: the specificity and incidence of endpoints from active and passive surveillance of children in rural Kenya.;citation_author=A Olotu;citation_author=G Fegan;citation_author=TN Williams;citation_author=P Sasi;citation_author=E Ogada;citation_journal_title=PLoS ONE;citation_volume=5;citation_number=5;citation_first_page=e15569;citation_publication_date=2010;"/> <meta name="citation_reference" content="citation_title=Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya.;citation_author=WP O'Meara;citation_author=P Bejon;citation_author=TW Mwangi;citation_author=EA Okiro;citation_author=N Peshu;citation_journal_title=Lancet;citation_volume=372;citation_number=372;citation_first_page=1555;citation_last_page=1562;citation_publication_date=2008;"/> <meta name="citation_reference" content="citation_title=Methods and techniques for clinical trials on antimalarial drug efficacy;citation_publication_date=2008;"/> <meta name="citation_reference" content="citation_title=Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.;citation_author=Q Bassat;citation_author=M Mulenga;citation_author=H Tinto;citation_author=P Piola;citation_author=S Borrmann;citation_journal_title=PLoS ONE;citation_volume=4;citation_number=4;citation_first_page=e7871;citation_publication_date=2009;"/> <meta name="citation_reference" content="citation_title=Genotyping of Plasmodium falciparum. PCR-RFLP analysis.;citation_author=I Felger;citation_author=HP Beck;citation_journal_title=Methods Mol Med;citation_volume=72;citation_number=72;citation_first_page=117;citation_last_page=129;citation_publication_date=2002;"/> <meta name="citation_reference" content="citation_title=Comparison of PCR-RFLP and Genescan-based genotyping for analyzing infection dynamics of Plasmodium falciparum.;citation_author=N Falk;citation_author=N Maire;citation_author=W Sama;citation_author=S Owusu-Agyei;citation_author=T Smith;citation_journal_title=Am J Trop Med Hyg;citation_volume=74;citation_number=74;citation_first_page=944;citation_last_page=950;citation_publication_date=2006;"/> <meta name="citation_reference" content="citation_title=Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number.;citation_author=RN Price;citation_author=AC Uhlemann;citation_author=A Brockman;citation_author=R McGready;citation_author=E Ashley;citation_journal_title=Lancet;citation_volume=364;citation_number=364;citation_first_page=438;citation_last_page=447;citation_publication_date=2004;"/> <meta name="citation_reference" content="citation_title=High throughput assay for the determination of lumefantrine in plasma.;citation_author=A Annerberg;citation_author=T Singtoroj;citation_author=P Tipmanee;citation_author=NJ White;citation_author=NP Day;citation_journal_title=J Chromatogr B Analyt Technol Biomed Life Sci;citation_volume=822;citation_number=822;citation_first_page=330;citation_last_page=333;citation_publication_date=2005;"/> <meta name="citation_reference" content="citation_title=Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects.;citation_author=N Lindegardh;citation_author=A Annerberg;citation_author=NJ White;citation_author=NP Day;citation_journal_title=J Chromatogr B Analyt Technol Biomed Life Sci;citation_volume=862;citation_number=862;citation_first_page=227;citation_last_page=236;citation_publication_date=2008;"/> <meta name="citation_reference" content="citation_title=Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.;citation_author=FH Osier;citation_author=G Fegan;citation_author=SD Polley;citation_author=L Murungi;citation_author=F Verra;citation_journal_title=Infect Immun;citation_volume=76;citation_number=76;citation_first_page=2240;citation_last_page=2248;citation_publication_date=2008;"/> <meta name="citation_reference" content="citation_title=Platelets kill intraerythrocytic malarial parasites and mediate survival to infection.;citation_author=BJ McMorran;citation_author=VM Marshall;citation_author=C de Graaf;citation_author=KE Drysdale;citation_author=M Shabbar;citation_journal_title=Science;citation_volume=323;citation_number=323;citation_first_page=797;citation_last_page=800;citation_publication_date=2009;"/> <meta name="citation_reference" content="citation_title=Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria.;citation_author=S Borrmann;citation_author=T Peto;citation_author=RW Snow;citation_author=W Gutteridge;citation_author=NJ White;citation_journal_title=Plos Med;citation_volume=5;citation_number=5;citation_first_page=e227;citation_publication_date=2008;"/> <meta name="citation_reference" content="citation_title=Antimalarial drug resistance.;citation_author=NJ White;citation_journal_title=J Clin Invest;citation_volume=113;citation_number=113;citation_first_page=1084;citation_last_page=1092;citation_publication_date=2004;"/> <meta name="citation_reference" content="citation_title=The perils of PCR: can we accurately ‘correct’ antimalarial trials?;citation_author=JJ Juliano;citation_author=N Gadalla;citation_author=CJ Sutherland;citation_author=SR Meshnick;citation_journal_title=Trends Parasitol;citation_volume=26;citation_number=26;citation_first_page=119;citation_last_page=124;citation_publication_date=2010;"/> <meta name="citation_reference" content="citation_title=World Malaria Report 2010;citation_publication_date=2010;"/> <meta name="citation_reference" content="citation_title=Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment.;citation_author=VI Carrara;citation_author=J Zwang;citation_author=EA Ashley;citation_author=RN Price;citation_author=K Stepniewska;citation_journal_title=PLoS ONE;citation_volume=4;citation_number=4;citation_first_page=e4551;citation_publication_date=2009;"/> <meta name="citation_reference" content="citation_title=Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity.;citation_author=WP O'Meara;citation_author=TW Mwangi;citation_author=TN Williams;citation_author=FE McKenzie;citation_author=RW Snow;citation_journal_title=Am J Trop Med Hyg;citation_volume=79;citation_number=79;citation_first_page=185;citation_last_page=191;citation_publication_date=2008;"/> <meta name="citation_reference" content="citation_title=Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in children.;citation_author=S Borrmann;citation_author=PB Matsiegui;citation_author=MA Missinou;citation_author=PG Kremsner;citation_journal_title=Antimicrob Agents Chemother;citation_volume=52;citation_number=52;citation_first_page=1799;citation_last_page=1805;citation_publication_date=2008;"/> <meta name="citation_reference" content="citation_title=Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria.;citation_author=AA Djimde;citation_author=OK Doumbo;citation_author=O Traore;citation_author=AB Guindo;citation_author=K Kayentao;citation_journal_title=Am J Trop Med Hyg;citation_volume=69;citation_number=69;citation_first_page=558;citation_last_page=563;citation_publication_date=2003;"/> <meta name="citation_reference" content="citation_title=Antibody responses to Plasmodium falciparum merozoite surface protein-1 and efficacy of amodiaquine in Gabonese children with P. falciparum malaria.;citation_author=DP Mawili-Mboumba;citation_author=S Borrmann;citation_author=DR Cavanagh;citation_author=JS McBride;citation_author=PB Matsiegui;citation_journal_title=J Infect Dis;citation_volume=187;citation_number=187;citation_first_page=1137;citation_last_page=1141;citation_publication_date=2003;"/> <meta name="citation_reference" content="citation_title=Contribution of humoral immunity to the therapeutic response in falciparum malaria.;citation_author=M Mayxay;citation_author=K Chotivanich;citation_author=S Pukrittayakamee;citation_author=P Newton;citation_author=S Looareesuwan;citation_journal_title=Am J Trop Med Hyg;citation_volume=65;citation_number=65;citation_first_page=918;citation_last_page=923;citation_publication_date=2001;"/> <meta name="citation_reference" content="citation_title=Antimalarial drugs clear resistant parasites from partially immune hosts.;citation_author=P Cravo;citation_author=R Culleton;citation_author=P Hunt;citation_author=D Walliker;citation_author=MJ Mackinnon;citation_journal_title=Antimicrob Agents Chemother;citation_volume=45;citation_number=45;citation_first_page=2897;citation_last_page=2901;citation_publication_date=2001;"/> <meta name="citation_reference" content="citation_title=High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia.;citation_author=TJ Anderson;citation_author=S Nair;citation_author=S Nkhoma;citation_author=JT Williams;citation_author=M Imwong;citation_journal_title=J Infect Dis;citation_volume=201;citation_number=201;citation_first_page=1326;citation_last_page=1330;citation_publication_date=2010;"/> <meta name="citation_reference" content="citation_title=Inferred relatedness and heritability in malaria parasites.;citation_author=TJ Anderson;citation_author=JT Williams;citation_author=S Nair;citation_author=D Sudimack;citation_author=M Barends;citation_journal_title=Proc Biol Sci;citation_publication_date=2010;"/> <meta name="citation_reference" content="citation_title=In vitro activity of piperaquine, lumefantrine and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in Pfcrt and Pfmdr1.;citation_author=L Mwai;citation_author=SM Kiara;citation_author=A Abdirahman;citation_author=L Pole;citation_author=A Rippert;citation_journal_title=Antimicrob Agents Chemother;citation_volume=53;citation_number=53;citation_first_page=5069;citation_last_page=5073;citation_publication_date=2009;"/> <meta name="citation_reference" content="citation_title=In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon.;citation_author=LK Basco;citation_author=P Ringwald;citation_journal_title=Antimicrob Agents Chemother;citation_volume=47;citation_number=47;citation_first_page=1391;citation_last_page=1394;citation_publication_date=2003;"/> <meta name="citation_reference" content="citation_title=In vitro sensitivity of Plasmodium falciparum to conventional and novel antimalarial drugs in Papua New Guinea.;citation_author=RP Wong;citation_author=D Lautu;citation_author=L Tavul;citation_author=SL Hackett;citation_author=P Siba;citation_journal_title=Trop Med Int Health;citation_volume=15;citation_number=15;citation_first_page=342;citation_last_page=349;citation_publication_date=2010;"/> <meta name="citation_reference" content="citation_title=Field observations on the antimalarial piperaquine.;citation_author=L Chen;citation_author=FY Qu;citation_author=YC Zhou;citation_journal_title=Chin Med J (Engl);citation_volume=95;citation_number=95;citation_first_page=281;citation_last_page=286;citation_publication_date=1982;"/> <meta name="citation_reference" content="citation_title=In vivo parasitological measures of artemisinin susceptibility.;citation_author=K Stepniewska;citation_author=E Ashley;citation_author=SJ Lee;citation_author=N Anstey;citation_author=KI Barnes;citation_journal_title=J Infect Dis;citation_volume=201;citation_number=201;citation_first_page=570;citation_last_page=579;citation_publication_date=2010;"/> <meta name="citation_reference" content="citation_title=Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.;citation_author=A Dondorp;citation_author=F Nosten;citation_author=K Stepniewska;citation_author=N Day;citation_author=N White;citation_journal_title=Lancet;citation_volume=366;citation_number=366;citation_first_page=717;citation_last_page=725;citation_publication_date=2005;"/>  <script type='text/javascript'> var googletag = googletag || {}; googletag.cmd = googletag.cmd || []; (function() { var gads = document.createElement('script'); gads.async = true; gads.type = 'text/javascript'; var useSSL = 'https:' == document.location.protocol; gads.src = (useSSL ? 'https:' : 'http:') + '//www.googletagservices.com/tag/js/gpt.js'; var node = document.getElementsByTagName('script')[0]; node.parentNode.insertBefore(gads, node); })(); </script>  <script id="doubleClickSetupScript" type='text/javascript'> googletag.cmd.push(function() { googletag.defineSlot('/75507958/PONE_728x90_ATF', [728, 90], 'div-gpt-ad-1458247671871-0').addService(googletag.pubads()); googletag.defineSlot('/75507958/PONE_160x600_BTF', [160, 600], 'div-gpt-ad-1458247671871-1').addService(googletag.pubads()); var personalizedAds = window.plosCookieConsent && window.plosCookieConsent.hasConsented('advertising'); googletag.pubads().setRequestNonPersonalizedAds(personalizedAds ? 0 : 1); googletag.pubads().enableSingleRequest(); googletag.enableServices(); }); </script> <script type="text/javascript"> var WombatConfig = WombatConfig || {}; WombatConfig.journalKey = "PLoSONE"; WombatConfig.journalName = "PLOS One"; WombatConfig.figurePath = "/plosone/article/figure/image"; WombatConfig.figShareInstitutionString = "plos"; WombatConfig.doiResolverPrefix = "https://dx.plos.org/"; </script> <script type="text/javascript"> var WombatConfig = WombatConfig || {}; WombatConfig.metrics = WombatConfig.metrics || {}; WombatConfig.metrics.referenceUrl = "http://lagotto.io/plos"; WombatConfig.metrics.googleScholarUrl = "https://scholar.google.com/scholar"; WombatConfig.metrics.googleScholarCitationUrl = WombatConfig.metrics.googleScholarUrl + "?hl=en&lr=&q="; WombatConfig.metrics.crossrefUrl = "https://www.crossref.org"; </script> <script defer="defer" src="/resource/js/defer.js?51fad052322a8bbab75f"></script><script src="/resource/js/sync.js?51fad052322a8bbab75f"></script> <script src="/resource/js/vendor/jquery.min.js" type="text/javascript"></script> <script type="text/javascript" src="https://widgets.figshare.com/static/figshare.js"></script> <script src="/resource/js/vendor/fastclick/lib/fastclick.js" type="text/javascript"></script> <script src="/resource/js/vendor/foundation/foundation.js" type="text/javascript"></script> <script src="/resource/js/vendor/underscore-min.js" type="text/javascript"></script> <script src="/resource/js/vendor/underscore.string.min.js" type="text/javascript"></script> <script src="/resource/js/vendor/moment.js" type="text/javascript"></script> <script src="/resource/js/vendor/jquery-ui-effects.min.js" type="text/javascript"></script> <script src="/resource/js/vendor/foundation/foundation.tooltip.js" type="text/javascript"></script> <script src="/resource/js/vendor/foundation/foundation.dropdown.js" type="text/javascript"></script> <script src="/resource/js/vendor/foundation/foundation.tab.js" type="text/javascript"></script> <script src="/resource/js/vendor/foundation/foundation.reveal.js" type="text/javascript"></script> <script src="/resource/js/vendor/foundation/foundation.slider.js" type="text/javascript"></script> <script src="/resource/js/util/utils.js" type="text/javascript"></script> <script src="/resource/js/components/toggle.js" type="text/javascript"></script> <script src="/resource/js/components/truncate_elem.js" type="text/javascript"></script> <script src="/resource/js/components/tooltip_hover.js" type="text/javascript"></script> <script src="/resource/js/vendor/jquery.dotdotdot.js" type="text/javascript"></script>  <script> dataLayer = [{ 'mobileSite': 'false', 'desktopSite': 'true' }]; </script> <title>Declining Responsiveness of Plasmodium falciparum Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast | PLOS One</title> </head> <body class="article plosone">  <noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-TP26BH" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <script> (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-TP26BH'); </script> <noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-MQQMGF" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MQQMGF');</script>   <script> // from https://developers.hubspot.com/docs/reference/api/analytics-and-events/cookie-banner/cookie-banner-api#example-using-a-third-party-cookie-banner-to-control-hubspot-cookies window.disableHubSpotCookieBanner = true; window._hsp = window._hsp || []; window._hsp.push(['setHubSpotConsent', { analytics: window.plosCookieConsent?.hasConsented('analytics'), advertisement: window.plosCookieConsent?.hasConsented('advertising'), functionality: window.plosCookieConsent?.hasConsented('functionality') } ]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/44092021.js"></script>   <script type="text/javascript"> ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var o=e[n]={exports:{}};t[n][0].call(o.exports,function(e){var o=t[n][1][e];return r(o||e)},o,o.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<n.length;o++)r(n[o]);return r}({1:[function(t,e,n){function r(t){try{s.console&&console.log(t)}catch(e){}}var o,i=t("ee"),a=t(32),s={};try{o=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(s.console=!0,o.indexOf("dev")!==-1&&(s.dev=!0),o.indexOf("nr_dev")!==-1&&(s.nrDev=!0))}catch(c){}s.nrDev&&i.on("internal-error",function(t){r(t.stack)}),s.dev&&i.on("fn-err",function(t,e,n){r(n.stack)}),s.dev&&(r("NR AGENT IN DEVELOPMENT MODE"),r("flags: "+a(s,function(t,e){return t}).join(", ")))},{}],2:[function(t,e,n){function r(t,e,n,r,s){try{l?l-=1:o(s||new UncaughtException(t,e,n),!0)}catch(f){try{i("ierr",[f,c.now(),!0])}catch(d){}}return"function"==typeof u&&u.apply(this,a(arguments))}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}function o(t,e){var n=e?null:c.now();i("err",[t,n])}var i=t("handle"),a=t(33),s=t("ee"),c=t("loader"),f=t("gos"),u=window.onerror,d=!1,p="nr@seenError";if(!c.disabled){var l=0;c.features.err=!0,t(1),window.onerror=r;try{throw new Error}catch(h){"stack"in h&&(t(14),t(13),"addEventListener"in window&&t(7),c.xhrWrappable&&t(15),d=!0)}s.on("fn-start",function(t,e,n){d&&(l+=1)}),s.on("fn-err",function(t,e,n){d&&!n[p]&&(f(n,p,function(){return!0}),this.thrown=!0,o(n))}),s.on("fn-end",function(){d&&!this.thrown&&l>0&&(l-=1)}),s.on("internal-error",function(t){i("ierr",[t,c.now(),!0])})}},{}],3:[function(t,e,n){var r=t("loader");r.disabled||(r.features.ins=!0)},{}],4:[function(t,e,n){function r(){U++,L=g.hash,this[u]=y.now()}function o(){U--,g.hash!==L&&i(0,!0);var t=y.now();this[h]=~~this[h]+t-this[u],this[d]=t}function i(t,e){E.emit("newURL",[""+g,e])}function a(t,e){t.on(e,function(){this[e]=y.now()})}var s="-start",c="-end",f="-body",u="fn"+s,d="fn"+c,p="cb"+s,l="cb"+c,h="jsTime",m="fetch",v="addEventListener",w=window,g=w.location,y=t("loader");if(w[v]&&y.xhrWrappable&&!y.disabled){var x=t(11),b=t(12),E=t(9),R=t(7),O=t(14),T=t(8),P=t(15),S=t(10),M=t("ee"),N=M.get("tracer"),C=t(23);t(17),y.features.spa=!0;var L,U=0;M.on(u,r),b.on(p,r),S.on(p,r),M.on(d,o),b.on(l,o),S.on(l,o),M.buffer([u,d,"xhr-resolved"]),R.buffer([u]),O.buffer(["setTimeout"+c,"clearTimeout"+s,u]),P.buffer([u,"new-xhr","send-xhr"+s]),T.buffer([m+s,m+"-done",m+f+s,m+f+c]),E.buffer(["newURL"]),x.buffer([u]),b.buffer(["propagate",p,l,"executor-err","resolve"+s]),N.buffer([u,"no-"+u]),S.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"]),a(T,m+s),a(T,m+"-done"),a(S,"new-jsonp"),a(S,"jsonp-end"),a(S,"cb-start"),E.on("pushState-end",i),E.on("replaceState-end",i),w[v]("hashchange",i,C(!0)),w[v]("load",i,C(!0)),w[v]("popstate",function(){i(0,U>1)},C(!0))}},{}],5:[function(t,e,n){function r(){var t=new PerformanceObserver(function(t,e){var n=t.getEntries();s(v,[n])});try{t.observe({entryTypes:["resource"]})}catch(e){}}function o(t){if(s(v,[window.performance.getEntriesByType(w)]),window.performance["c"+p])try{window.performance[h](m,o,!1)}catch(t){}else try{window.performance[h]("webkit"+m,o,!1)}catch(t){}}function i(t){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var a=t("ee"),s=t("handle"),c=t(14),f=t(13),u=t(6),d=t(23),p="learResourceTimings",l="addEventListener",h="removeEventListener",m="resourcetimingbufferfull",v="bstResource",w="resource",g="-start",y="-end",x="fn"+g,b="fn"+y,E="bstTimer",R="pushState",O=t("loader");if(!O.disabled){O.features.stn=!0,t(9),"addEventListener"in window&&t(7);var T=NREUM.o.EV;a.on(x,function(t,e){var n=t[0];n instanceof T&&(this.bstStart=O.now())}),a.on(b,function(t,e){var n=t[0];n instanceof T&&s("bst",[n,e,this.bstStart,O.now()])}),c.on(x,function(t,e,n){this.bstStart=O.now(),this.bstType=n}),c.on(b,function(t,e){s(E,[e,this.bstStart,O.now(),this.bstType])}),f.on(x,function(){this.bstStart=O.now()}),f.on(b,function(t,e){s(E,[e,this.bstStart,O.now(),"requestAnimationFrame"])}),a.on(R+g,function(t){this.time=O.now(),this.startPath=location.pathname+location.hash}),a.on(R+y,function(t){s("bstHist",[location.pathname+location.hash,this.startPath,this.time])}),u()?(s(v,[window.performance.getEntriesByType("resource")]),r()):l in window.performance&&(window.performance["c"+p]?window.performance[l](m,o,d(!1)):window.performance[l]("webkit"+m,o,d(!1))),document[l]("scroll",i,d(!1)),document[l]("keypress",i,d(!1)),document[l]("click",i,d(!1))}}},{}],6:[function(t,e,n){e.exports=function(){return"PerformanceObserver"in window&&"function"==typeof window.PerformanceObserver}},{}],7:[function(t,e,n){function r(t){for(var e=t;e&&!e.hasOwnProperty(u);)e=Object.getPrototypeOf(e);e&&o(e)}function o(t){s.inPlace(t,[u,d],"-",i)}function i(t,e){return t[1]}var a=t("ee").get("events"),s=t("wrap-function")(a,!0),c=t("gos"),f=XMLHttpRequest,u="addEventListener",d="removeEventListener";e.exports=a,"getPrototypeOf"in Object?(r(document),r(window),r(f.prototype)):f.prototype.hasOwnProperty(u)&&(o(window),o(f.prototype)),a.on(u+"-start",function(t,e){var n=t[1];if(null!==n&&("function"==typeof n||"object"==typeof n)){var r=c(n,"nr@wrapped",function(){function t(){if("function"==typeof n.handleEvent)return n.handleEvent.apply(n,arguments)}var e={object:t,"function":n}[typeof n];return e?s(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=t[1]=r}}),a.on(d+"-start",function(t){t[1]=this.wrapped||t[1]})},{}],8:[function(t,e,n){function r(t,e,n){var r=t[e];"function"==typeof r&&(t[e]=function(){var t=i(arguments),e={};o.emit(n+"before-start",[t],e);var a;e[m]&&e[m].dt&&(a=e[m].dt);var s=r.apply(this,t);return o.emit(n+"start",[t,a],s),s.then(function(t){return o.emit(n+"end",[null,t],s),t},function(t){throw o.emit(n+"end",[t],s),t})})}var o=t("ee").get("fetch"),i=t(33),a=t(32);e.exports=o;var s=window,c="fetch-",f=c+"body-",u=["arrayBuffer","blob","json","text","formData"],d=s.Request,p=s.Response,l=s.fetch,h="prototype",m="nr@context";d&&p&&l&&(a(u,function(t,e){r(d[h],e,f),r(p[h],e,f)}),r(s,"fetch",c),o.on(c+"end",function(t,e){var n=this;if(e){var r=e.headers.get("content-length");null!==r&&(n.rxSize=r),o.emit(c+"done",[null,e],n)}else o.emit(c+"done",[t],n)}))},{}],9:[function(t,e,n){var r=t("ee").get("history"),o=t("wrap-function")(r);e.exports=r;var i=window.history&&window.history.constructor&&window.history.constructor.prototype,a=window.history;i&&i.pushState&&i.replaceState&&(a=i),o.inPlace(a,["pushState","replaceState"],"-")},{}],10:[function(t,e,n){function r(t){function e(){f.emit("jsonp-end",[],l),t.removeEventListener("load",e,c(!1)),t.removeEventListener("error",n,c(!1))}function n(){f.emit("jsonp-error",[],l),f.emit("jsonp-end",[],l),t.removeEventListener("load",e,c(!1)),t.removeEventListener("error",n,c(!1))}var r=t&&"string"==typeof t.nodeName&&"script"===t.nodeName.toLowerCase();if(r){var o="function"==typeof t.addEventListener;if(o){var a=i(t.src);if(a){var d=s(a),p="function"==typeof d.parent[d.key];if(p){var l={};u.inPlace(d.parent,[d.key],"cb-",l),t.addEventListener("load",e,c(!1)),t.addEventListener("error",n,c(!1)),f.emit("new-jsonp",[t.src],l)}}}}}function o(){return"addEventListener"in window}function i(t){var e=t.match(d);return e?e[1]:null}function a(t,e){var n=t.match(l),r=n[1],o=n[3];return o?a(o,e[r]):e[r]}function s(t){var e=t.match(p);return e&&e.length>=3?{key:e[2],parent:a(e[1],window)}:{key:t,parent:window}}var c=t(23),f=t("ee").get("jsonp"),u=t("wrap-function")(f);if(e.exports=f,o()){var d=/[?&](?:callback|cb)=([^&#]+)/,p=/(.*)\.([^.]+)/,l=/^(\w+)(\.|$)(.*)$/,h=["appendChild","insertBefore","replaceChild"];Node&&Node.prototype&&Node.prototype.appendChild?u.inPlace(Node.prototype,h,"dom-"):(u.inPlace(HTMLElement.prototype,h,"dom-"),u.inPlace(HTMLHeadElement.prototype,h,"dom-"),u.inPlace(HTMLBodyElement.prototype,h,"dom-")),f.on("dom-start",function(t){r(t[0])})}},{}],11:[function(t,e,n){var r=t("ee").get("mutation"),o=t("wrap-function")(r),i=NREUM.o.MO;e.exports=r,i&&(window.MutationObserver=function(t){return this instanceof i?new i(o(t,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype)},{}],12:[function(t,e,n){function r(t){var e=i.context(),n=s(t,"executor-",e,null,!1),r=new f(n);return i.context(r).getCtx=function(){return e},r}var o=t("wrap-function"),i=t("ee").get("promise"),a=t("ee").getOrSetContext,s=o(i),c=t(32),f=NREUM.o.PR;e.exports=i,f&&(window.Promise=r,["all","race"].forEach(function(t){var e=f[t];f[t]=function(n){function r(t){return function(){i.emit("propagate",[null,!o],a,!1,!1),o=o||!t}}var o=!1;c(n,function(e,n){Promise.resolve(n).then(r("all"===t),r(!1))});var a=e.apply(f,arguments),s=f.resolve(a);return s}}),["resolve","reject"].forEach(function(t){var e=f[t];f[t]=function(t){var n=e.apply(f,arguments);return t!==n&&i.emit("propagate",[t,!0],n,!1,!1),n}}),f.prototype["catch"]=function(t){return this.then(null,t)},f.prototype=Object.create(f.prototype,{constructor:{value:r}}),c(Object.getOwnPropertyNames(f),function(t,e){try{r[e]=f[e]}catch(n){}}),o.wrapInPlace(f.prototype,"then",function(t){return function(){var e=this,n=o.argsToArray.apply(this,arguments),r=a(e);r.promise=e,n[0]=s(n[0],"cb-",r,null,!1),n[1]=s(n[1],"cb-",r,null,!1);var c=t.apply(this,n);return r.nextPromise=c,i.emit("propagate",[e,!0],c,!1,!1),c}}),i.on("executor-start",function(t){t[0]=s(t[0],"resolve-",this,null,!1),t[1]=s(t[1],"resolve-",this,null,!1)}),i.on("executor-err",function(t,e,n){t[1](n)}),i.on("cb-end",function(t,e,n){i.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),i.on("propagate",function(t,e,n){this.getCtx&&!e||(this.getCtx=function(){if(t instanceof Promise)var e=i.context(t);return e&&e.getCtx?e.getCtx():this})}),r.toString=function(){return""+f})},{}],13:[function(t,e,n){var r=t("ee").get("raf"),o=t("wrap-function")(r),i="equestAnimationFrame";e.exports=r,o.inPlace(window,["r"+i,"mozR"+i,"webkitR"+i,"msR"+i],"raf-"),r.on("raf-start",function(t){t[0]=o(t[0],"fn-")})},{}],14:[function(t,e,n){function r(t,e,n){t[0]=a(t[0],"fn-",null,n)}function o(t,e,n){this.method=n,this.timerDuration=isNaN(t[1])?0:+t[1],t[0]=a(t[0],"fn-",this,n)}var i=t("ee").get("timer"),a=t("wrap-function")(i),s="setTimeout",c="setInterval",f="clearTimeout",u="-start",d="-";e.exports=i,a.inPlace(window,[s,"setImmediate"],s+d),a.inPlace(window,[c],c+d),a.inPlace(window,[f,"clearImmediate"],f+d),i.on(c+u,r),i.on(s+u,o)},{}],15:[function(t,e,n){function r(t,e){d.inPlace(e,["onreadystatechange"],"fn-",s)}function o(){var t=this,e=u.context(t);t.readyState>3&&!e.resolved&&(e.resolved=!0,u.emit("xhr-resolved",[],t)),d.inPlace(t,y,"fn-",s)}function i(t){x.push(t),m&&(E?E.then(a):w?w(a):(R=-R,O.data=R))}function a(){for(var t=0;t<x.length;t++)r([],x[t]);x.length&&(x=[])}function s(t,e){return e}function c(t,e){for(var n in t)e[n]=t[n];return e}t(7);var f=t("ee"),u=f.get("xhr"),d=t("wrap-function")(u),p=t(23),l=NREUM.o,h=l.XHR,m=l.MO,v=l.PR,w=l.SI,g="readystatechange",y=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],x=[];e.exports=u;var b=window.XMLHttpRequest=function(t){var e=new h(t);try{u.emit("new-xhr",[e],e),e.addEventListener(g,o,p(!1))}catch(n){try{u.emit("internal-error",[n])}catch(r){}}return e};if(c(h,b),b.prototype=h.prototype,d.inPlace(b.prototype,["open","send"],"-xhr-",s),u.on("send-xhr-start",function(t,e){r(t,e),i(e)}),u.on("open-xhr-start",r),m){var E=v&&v.resolve();if(!w&&!v){var R=1,O=document.createTextNode(R);new m(a).observe(O,{characterData:!0})}}else f.on("fn-end",function(t){t[0]&&t[0].type===g||a()})},{}],16:[function(t,e,n){function r(t){if(!s(t))return null;var e=window.NREUM;if(!e.loader_config)return null;var n=(e.loader_config.accountID||"").toString()||null,r=(e.loader_config.agentID||"").toString()||null,f=(e.loader_config.trustKey||"").toString()||null;if(!n||!r)return null;var h=l.generateSpanId(),m=l.generateTraceId(),v=Date.now(),w={spanId:h,traceId:m,timestamp:v};return(t.sameOrigin||c(t)&&p())&&(w.traceContextParentHeader=o(h,m),w.traceContextStateHeader=i(h,v,n,r,f)),(t.sameOrigin&&!u()||!t.sameOrigin&&c(t)&&d())&&(w.newrelicHeader=a(h,m,v,n,r,f)),w}function o(t,e){return"00-"+e+"-"+t+"-01"}function i(t,e,n,r,o){var i=0,a="",s=1,c="",f="";return o+"@nr="+i+"-"+s+"-"+n+"-"+r+"-"+t+"-"+a+"-"+c+"-"+f+"-"+e}function a(t,e,n,r,o,i){var a="btoa"in window&&"function"==typeof window.btoa;if(!a)return null;var s={v:[0,1],d:{ty:"Browser",ac:r,ap:o,id:t,tr:e,ti:n}};return i&&r!==i&&(s.d.tk=i),btoa(JSON.stringify(s))}function s(t){return f()&&c(t)}function c(t){var e=!1,n={};if("init"in NREUM&&"distributed_tracing"in NREUM.init&&(n=NREUM.init.distributed_tracing),t.sameOrigin)e=!0;else if(n.allowed_origins instanceof Array)for(var r=0;r<n.allowed_origins.length;r++){var o=h(n.allowed_origins[r]);if(t.hostname===o.hostname&&t.protocol===o.protocol&&t.port===o.port){e=!0;break}}return e}function f(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.enabled}function u(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.exclude_newrelic_header}function d(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&NREUM.init.distributed_tracing.cors_use_newrelic_header!==!1}function p(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.cors_use_tracecontext_headers}var l=t(29),h=t(18);e.exports={generateTracePayload:r,shouldGenerateTrace:s}},{}],17:[function(t,e,n){function r(t){var e=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var r=0;r<p;r++)t.removeEventListener(d[r],this.listener,!1);e.aborted||(n.duration=a.now()-this.startTime,this.loadCaptureCalled||4!==t.readyState?null==e.status&&(e.status=0):i(this,t),n.cbTime=this.cbTime,s("xhr",[e,n,this.startTime,this.endTime,"xhr"],this))}}function o(t,e){var n=c(e),r=t.params;r.hostname=n.hostname,r.port=n.port,r.protocol=n.protocol,r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.parsedOrigin=n,t.sameOrigin=n.sameOrigin}function i(t,e){t.params.status=e.status;var n=v(e,t.lastSize);if(n&&(t.metrics.rxSize=n),t.sameOrigin){var r=e.getResponseHeader("X-NewRelic-App-Data");r&&(t.params.cat=r.split(", ").pop())}t.loadCaptureCalled=!0}var a=t("loader");if(a.xhrWrappable&&!a.disabled){var s=t("handle"),c=t(18),f=t(16).generateTracePayload,u=t("ee"),d=["load","error","abort","timeout"],p=d.length,l=t("id"),h=t(24),m=t(22),v=t(19),w=t(23),g=NREUM.o.REQ,y=window.XMLHttpRequest;a.features.xhr=!0,t(15),t(8),u.on("new-xhr",function(t){var e=this;e.totalCbs=0,e.called=0,e.cbTime=0,e.end=r,e.ended=!1,e.xhrGuids={},e.lastSize=null,e.loadCaptureCalled=!1,e.params=this.params||{},e.metrics=this.metrics||{},t.addEventListener("load",function(n){i(e,t)},w(!1)),h&&(h>34||h<10)||t.addEventListener("progress",function(t){e.lastSize=t.loaded},w(!1))}),u.on("open-xhr-start",function(t){this.params={method:t[0]},o(this,t[1]),this.metrics={}}),u.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid);var n=f(this.parsedOrigin);if(n){var r=!1;n.newrelicHeader&&(e.setRequestHeader("newrelic",n.newrelicHeader),r=!0),n.traceContextParentHeader&&(e.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&e.setRequestHeader("tracestate",n.traceContextStateHeader),r=!0),r&&(this.dt=n)}}),u.on("send-xhr-start",function(t,e){var n=this.metrics,r=t[0],o=this;if(n&&r){var i=m(r);i&&(n.txSize=i)}this.startTime=a.now(),this.listener=function(t){try{"abort"!==t.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==t.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof e.onload))&&o.end(e)}catch(n){try{u.emit("internal-error",[n])}catch(r){}}};for(var s=0;s<p;s++)e.addEventListener(d[s],this.listener,w(!1))}),u.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),u.on("xhr-load-added",function(t,e){var n=""+l(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),u.on("xhr-load-removed",function(t,e){var n=""+l(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),u.on("xhr-resolved",function(){this.endTime=a.now()}),u.on("addEventListener-end",function(t,e){e instanceof y&&"load"===t[0]&&u.emit("xhr-load-added",[t[1],t[2]],e)}),u.on("removeEventListener-end",function(t,e){e instanceof y&&"load"===t[0]&&u.emit("xhr-load-removed",[t[1],t[2]],e)}),u.on("fn-start",function(t,e,n){e instanceof y&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=a.now()))}),u.on("fn-end",function(t,e){this.xhrCbStart&&u.emit("xhr-cb-time",[a.now()-this.xhrCbStart,this.onload,e],e)}),u.on("fetch-before-start",function(t){function e(t,e){var n=!1;return e.newrelicHeader&&(t.set("newrelic",e.newrelicHeader),n=!0),e.traceContextParentHeader&&(t.set("traceparent",e.traceContextParentHeader),e.traceContextStateHeader&&t.set("tracestate",e.traceContextStateHeader),n=!0),n}var n,r=t[1]||{};"string"==typeof t[0]?n=t[0]:t[0]&&t[0].url?n=t[0].url:window.URL&&t[0]&&t[0]instanceof URL&&(n=t[0].href),n&&(this.parsedOrigin=c(n),this.sameOrigin=this.parsedOrigin.sameOrigin);var o=f(this.parsedOrigin);if(o&&(o.newrelicHeader||o.traceContextParentHeader))if("string"==typeof t[0]||window.URL&&t[0]&&t[0]instanceof URL){var i={};for(var a in r)i[a]=r[a];i.headers=new Headers(r.headers||{}),e(i.headers,o)&&(this.dt=o),t.length>1?t[1]=i:t.push(i)}else t[0]&&t[0].headers&&e(t[0].headers,o)&&(this.dt=o)}),u.on("fetch-start",function(t,e){this.params={},this.metrics={},this.startTime=a.now(),this.dt=e,t.length>=1&&(this.target=t[0]),t.length>=2&&(this.opts=t[1]);var n,r=this.opts||{},i=this.target;"string"==typeof i?n=i:"object"==typeof i&&i instanceof g?n=i.url:window.URL&&"object"==typeof i&&i instanceof URL&&(n=i.href),o(this,n);var s=(""+(i&&i instanceof g&&i.method||r.method||"GET")).toUpperCase();this.params.method=s,this.txSize=m(r.body)||0}),u.on("fetch-done",function(t,e){this.endTime=a.now(),this.params||(this.params={}),this.params.status=e?e.status:0;var n;"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var r={txSize:this.txSize,rxSize:n,duration:a.now()-this.startTime};s("xhr",[this.params,r,this.startTime,this.endTime,"fetch"],this)})}},{}],18:[function(t,e,n){var r={};e.exports=function(t){if(t in r)return r[t];var e=document.createElement("a"),n=window.location,o={};e.href=t,o.port=e.port;var i=e.href.split("://");!o.port&&i[1]&&(o.port=i[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===i[0]?"443":"80"),o.hostname=e.hostname||n.hostname,o.pathname=e.pathname,o.protocol=i[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var a=!e.protocol||":"===e.protocol||e.protocol===n.protocol,s=e.hostname===document.domain&&e.port===n.port;return o.sameOrigin=a&&(!e.hostname||s),"/"===o.pathname&&(r[t]=o),o}},{}],19:[function(t,e,n){function r(t,e){var n=t.responseType;return"json"===n&&null!==e?e:"arraybuffer"===n||"blob"===n||"json"===n?o(t.response):"text"===n||""===n||void 0===n?o(t.responseText):void 0}var o=t(22);e.exports=r},{}],20:[function(t,e,n){function r(){}function o(t,e,n,r){return function(){return u.recordSupportability("API/"+e+"/called"),i(t+e,[f.now()].concat(s(arguments)),n?null:this,r),n?void 0:this}}var i=t("handle"),a=t(32),s=t(33),c=t("ee").get("tracer"),f=t("loader"),u=t(25),d=NREUM;"undefined"==typeof window.newrelic&&(newrelic=d);var p=["setPageViewName","setCustomAttribute","setErrorHandler","finished","addToTrace","inlineHit","addRelease"],l="api-",h=l+"ixn-";a(p,function(t,e){d[e]=o(l,e,!0,"api")}),d.addPageAction=o(l,"addPageAction",!0),d.setCurrentRouteName=o(l,"routeName",!0),e.exports=newrelic,d.interaction=function(){return(new r).get()};var m=r.prototype={createTracer:function(t,e){var n={},r=this,o="function"==typeof e;return i(h+"tracer",[f.now(),t,n],r),function(){if(c.emit((o?"":"no-")+"fn-start",[f.now(),r,o],n),o)try{return e.apply(this,arguments)}catch(t){throw c.emit("fn-err",[arguments,this,t],n),t}finally{c.emit("fn-end",[f.now()],n)}}}};a("actionText,setName,setAttribute,save,ignore,onEnd,getContext,end,get".split(","),function(t,e){m[e]=o(h,e)}),newrelic.noticeError=function(t,e){"string"==typeof t&&(t=new Error(t)),u.recordSupportability("API/noticeError/called"),i("err",[t,f.now(),!1,e])}},{}],21:[function(t,e,n){function r(t){if(NREUM.init){for(var e=NREUM.init,n=t.split("."),r=0;r<n.length-1;r++)if(e=e[n[r]],"object"!=typeof e)return;return e=e[n[n.length-1]]}}e.exports={getConfiguration:r}},{}],22:[function(t,e,n){e.exports=function(t){if("string"==typeof t&&t.length)return t.length;if("object"==typeof t){if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if(!("undefined"!=typeof FormData&&t instanceof FormData))try{return JSON.stringify(t).length}catch(e){return}}}},{}],23:[function(t,e,n){var r=!1;try{var o=Object.defineProperty({},"passive",{get:function(){r=!0}});window.addEventListener("testPassive",null,o),window.removeEventListener("testPassive",null,o)}catch(i){}e.exports=function(t){return r?{passive:!0,capture:!!t}:!!t}},{}],24:[function(t,e,n){var r=0,o=navigator.userAgent.match(/Firefox[\/\s](\d+\.\d+)/);o&&(r=+o[1]),e.exports=r},{}],25:[function(t,e,n){function r(t,e){var n=[a,t,{name:t},e];return i("storeMetric",n,null,"api"),n}function o(t,e){var n=[s,t,{name:t},e];return i("storeEventMetrics",n,null,"api"),n}var i=t("handle"),a="sm",s="cm";e.exports={constants:{SUPPORTABILITY_METRIC:a,CUSTOM_METRIC:s},recordSupportability:r,recordCustom:o}},{}],26:[function(t,e,n){function r(){return s.exists&&performance.now?Math.round(performance.now()):(i=Math.max((new Date).getTime(),i))-a}function o(){return i}var i=(new Date).getTime(),a=i,s=t(34);e.exports=r,e.exports.offset=a,e.exports.getLastTimestamp=o},{}],27:[function(t,e,n){function r(t){return!(!t||!t.protocol||"file:"===t.protocol)}e.exports=r},{}],28:[function(t,e,n){function r(t,e){var n=t.getEntries();n.forEach(function(t){"first-paint"===t.name?p("timing",["fp",Math.floor(t.startTime)]):"first-contentful-paint"===t.name&&p("timing",["fcp",Math.floor(t.startTime)])})}function o(t,e){var n=t.getEntries();if(n.length>0){var r=n[n.length-1];if(c&&c<r.startTime)return;p("lcp",[r])}}function i(t){t.getEntries().forEach(function(t){t.hadRecentInput||p("cls",[t])})}function a(t){if(t instanceof v&&!g){var e=Math.round(t.timeStamp),n={type:t.type};e<=l.now()?n.fid=l.now()-e:e>l.offset&&e<=Date.now()?(e-=l.offset,n.fid=l.now()-e):e=l.now(),g=!0,p("timing",["fi",e,n])}}function s(t){"hidden"===t&&(c=l.now(),p("pageHide",[c]))}if(!("init"in NREUM&&"page_view_timing"in NREUM.init&&"enabled"in NREUM.init.page_view_timing&&NREUM.init.page_view_timing.enabled===!1)){var c,f,u,d,p=t("handle"),l=t("loader"),h=t(31),m=t(23),v=NREUM.o.EV;if("PerformanceObserver"in window&&"function"==typeof window.PerformanceObserver){f=new PerformanceObserver(r);try{f.observe({entryTypes:["paint"]})}catch(w){}u=new PerformanceObserver(o);try{u.observe({entryTypes:["largest-contentful-paint"]})}catch(w){}d=new PerformanceObserver(i);try{d.observe({type:"layout-shift",buffered:!0})}catch(w){}}if("addEventListener"in document){var g=!1,y=["click","keydown","mousedown","pointerdown","touchstart"];y.forEach(function(t){document.addEventListener(t,a,m(!1))})}h(s)}},{}],29:[function(t,e,n){function r(){function t(){return e?15&e[n++]:16*Math.random()|0}var e=null,n=0,r=window.crypto||window.msCrypto;r&&r.getRandomValues&&(e=r.getRandomValues(new Uint8Array(31)));for(var o,i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx",a="",s=0;s<i.length;s++)o=i[s],"x"===o?a+=t().toString(16):"y"===o?(o=3&t()|8,a+=o.toString(16)):a+=o;return a}function o(){return a(16)}function i(){return a(32)}function a(t){function e(){return n?15&n[r++]:16*Math.random()|0}var n=null,r=0,o=window.crypto||window.msCrypto;o&&o.getRandomValues&&Uint8Array&&(n=o.getRandomValues(new Uint8Array(31)));for(var i=[],a=0;a<t;a++)i.push(e().toString(16));return i.join("")}e.exports={generateUuid:r,generateSpanId:o,generateTraceId:i}},{}],30:[function(t,e,n){function r(t,e){if(!o)return!1;if(t!==o)return!1;if(!e)return!0;if(!i)return!1;for(var n=i.split("."),r=e.split("."),a=0;a<r.length;a++)if(r[a]!==n[a])return!1;return!0}var o=null,i=null,a=/Version\/(\S+)\s+Safari/;if(navigator.userAgent){var s=navigator.userAgent,c=s.match(a);c&&s.indexOf("Chrome")===-1&&s.indexOf("Chromium")===-1&&(o="Safari",i=c[1])}e.exports={agent:o,version:i,match:r}},{}],31:[function(t,e,n){function r(t){function e(){t(s&&document[s]?document[s]:document[i]?"hidden":"visible")}"addEventListener"in document&&a&&document.addEventListener(a,e,o(!1))}var o=t(23);e.exports=r;var i,a,s;"undefined"!=typeof document.hidden?(i="hidden",a="visibilitychange",s="visibilityState"):"undefined"!=typeof document.msHidden?(i="msHidden",a="msvisibilitychange"):"undefined"!=typeof document.webkitHidden&&(i="webkitHidden",a="webkitvisibilitychange",s="webkitVisibilityState")},{}],32:[function(t,e,n){function r(t,e){var n=[],r="",i=0;for(r in t)o.call(t,r)&&(n[i]=e(r,t[r]),i+=1);return n}var o=Object.prototype.hasOwnProperty;e.exports=r},{}],33:[function(t,e,n){function r(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,o=n-e||0,i=Array(o<0?0:o);++r<o;)i[r]=t[e+r];return i}e.exports=r},{}],34:[function(t,e,n){e.exports={exists:"undefined"!=typeof window.performance&&window.performance.timing&&"undefined"!=typeof window.performance.timing.navigationStart}},{}],ee:[function(t,e,n){function r(){}function o(t){function e(t){return t&&t instanceof r?t:t?f(t,c,a):a()}function n(n,r,o,i,a){if(a!==!1&&(a=!0),!l.aborted||i){t&&a&&t(n,r,o);for(var s=e(o),c=m(n),f=c.length,u=0;u<f;u++)c[u].apply(s,r);var p=d[y[n]];return p&&p.push([x,n,r,s]),s}}function i(t,e){g[t]=m(t).concat(e)}function h(t,e){var n=g[t];if(n)for(var r=0;r<n.length;r++)n[r]===e&&n.splice(r,1)}function m(t){return g[t]||[]}function v(t){return p[t]=p[t]||o(n)}function w(t,e){l.aborted||u(t,function(t,n){e=e||"feature",y[n]=e,e in d||(d[e]=[])})}var g={},y={},x={on:i,addEventListener:i,removeEventListener:h,emit:n,get:v,listeners:m,context:e,buffer:w,abort:s,aborted:!1};return x}function i(t){return f(t,c,a)}function a(){return new r}function s(){(d.api||d.feature)&&(l.aborted=!0,d=l.backlog={})}var c="nr@context",f=t("gos"),u=t(32),d={},p={},l=e.exports=o();e.exports.getOrSetContext=i,l.backlog=d},{}],gos:[function(t,e,n){function r(t,e,n){if(o.call(t,e))return t[e];var r=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:r,writable:!0,enumerable:!1}),r}catch(i){}return t[e]=r,r}var o=Object.prototype.hasOwnProperty;e.exports=r},{}],handle:[function(t,e,n){function r(t,e,n,r){o.buffer([t],r),o.emit(t,e,n)}var o=t("ee").get("handle");e.exports=r,r.ee=o},{}],id:[function(t,e,n){function r(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:a(t,i,function(){return o++})}var o=1,i="nr@id",a=t("gos");e.exports=r},{}],loader:[function(t,e,n){function r(){if(!P++){var t=T.info=NREUM.info,e=v.getElementsByTagName("script")[0];if(setTimeout(f.abort,3e4),!(t&&t.licenseKey&&t.applicationID&&e))return f.abort();c(R,function(e,n){t[e]||(t[e]=n)});var n=a();s("mark",["onload",n+T.offset],null,"api"),s("timing",["load",n]);var r=v.createElement("script");0===t.agent.indexOf("http://")||0===t.agent.indexOf("https://")?r.src=t.agent:r.src=h+"://"+t.agent,e.parentNode.insertBefore(r,e)}}function o(){"complete"===v.readyState&&i()}function i(){s("mark",["domContent",a()+T.offset],null,"api")}var a=t(26),s=t("handle"),c=t(32),f=t("ee"),u=t(30),d=t(27),p=t(21),l=t(23),h=p.getConfiguration("ssl")===!1?"http":"https",m=window,v=m.document,w="addEventListener",g="attachEvent",y=m.XMLHttpRequest,x=y&&y.prototype,b=!d(m.location);NREUM.o={ST:setTimeout,SI:m.setImmediate,CT:clearTimeout,XHR:y,REQ:m.Request,EV:m.Event,PR:m.Promise,MO:m.MutationObserver};var E=""+location,R={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-spa-1212.min.js"},O=y&&x&&x[w]&&!/CriOS/.test(navigator.userAgent),T=e.exports={offset:a.getLastTimestamp(),now:a,origin:E,features:{},xhrWrappable:O,userAgent:u,disabled:b};if(!b){t(20),t(28),v[w]?(v[w]("DOMContentLoaded",i,l(!1)),m[w]("load",r,l(!1))):(v[g]("onreadystatechange",o),m[g]("onload",r)),s("mark",["firstbyte",a.getLastTimestamp()],null,"api");var P=0}},{}],"wrap-function":[function(t,e,n){function r(t,e){function n(e,n,r,c,f){function nrWrapper(){var i,a,u,p;try{a=this,i=d(arguments),u="function"==typeof r?r(i,a):r||{}}catch(l){o([l,"",[i,a,c],u],t)}s(n+"start",[i,a,c],u,f);try{return p=e.apply(a,i)}catch(h){throw s(n+"err",[i,a,h],u,f),h}finally{s(n+"end",[i,a,p],u,f)}}return a(e)?e:(n||(n=""),nrWrapper[p]=e,i(e,nrWrapper,t),nrWrapper)}function r(t,e,r,o,i){r||(r="");var s,c,f,u="-"===r.charAt(0);for(f=0;f<e.length;f++)c=e[f],s=t[c],a(s)||(t[c]=n(s,u?c+r:r,o,c,i))}function s(n,r,i,a){if(!h||e){var s=h;h=!0;try{t.emit(n,r,i,e,a)}catch(c){o([c,n,r,i],t)}h=s}}return t||(t=u),n.inPlace=r,n.flag=p,n}function o(t,e){e||(e=u);try{e.emit("internal-error",t)}catch(n){}}function i(t,e,n){if(Object.defineProperty&&Object.keys)try{var r=Object.keys(t);return r.forEach(function(n){Object.defineProperty(e,n,{get:function(){return t[n]},set:function(e){return t[n]=e,e}})}),e}catch(i){o([i],n)}for(var a in t)l.call(t,a)&&(e[a]=t[a]);return e}function a(t){return!(t&&t instanceof Function&&t.apply&&!t[p])}function s(t,e){var n=e(t);return n[p]=t,i(t,n,u),n}function c(t,e,n){var r=t[e];t[e]=s(r,n)}function f(){for(var t=arguments.length,e=new Array(t),n=0;n<t;++n)e[n]=arguments[n];return e}var u=t("ee"),d=t(33),p="nr@original",l=Object.prototype.hasOwnProperty,h=!1;e.exports=r,e.exports.wrapFunction=s,e.exports.wrapInPlace=c,e.exports.argsToArray=f},{}]},{},["loader",2,17,5,3,4]); ;NREUM.loader_config={accountID:"804283",trustKey:"804283",agentID:"402703674",licenseKey:"cf99e8d2a3",applicationID:"402703674"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"cf99e8d2a3", // Modified this value from the generated script, to pass prod vs dev applicationID: window.location.hostname.includes('journals.plos.org') ? "402703674" : "402694889", sa:1} </script>  <header> <div id="topslot" class="head-top"> <a id="skip-to-content" tabindex="0" class="button" href="#main-content"> Skip to main content </a> <div class="center"> <div class="title">Advertisement</div>  <div class='advertisement' id='div-gpt-ad-1458247671871-0' style='width:728px; height:90px;'> <script type='text/javascript'> googletag.cmd.push(function() { googletag.display('div-gpt-ad-1458247671871-0'); }); </script> </div> </div> </div> <div id="user" class="nav" data-user-management-url="https://community.plos.org"> </div> <div id="pagehdr"> <nav class="nav-main"> <h1 class="logo"> <a href="/plosone/.">PLOS One</a> </h1> <section class="top-bar-section"> <ul class="nav-elements"> <li class="multi-col-parent menu-section-header has-dropdown" id="publish"> Publish <div class="dropdown mega "> <ul class="multi-col" id="publish-dropdown-list"> <li class="menu-section-header " id="submissions"> <span class="menu-section-header-title"> Submissions </span> <ul class="menu-section " id="submissions-dropdown-list"> <li> <a href="/plosone/s/getting-started" >Getting Started</a> </li> <li> <a href="/plosone/s/submission-guidelines" >Submission Guidelines</a> </li> <li> <a href="/plosone/s/figures" >Figures</a> </li> <li> <a href="/plosone/s/tables" >Tables</a> </li> <li> <a href="/plosone/s/supporting-information" >Supporting Information</a> </li> <li> <a href="/plosone/s/latex" >LaTeX</a> </li> <li> <a href="/plosone/s/what-we-publish" >What We Publish</a> </li> <li> <a href="/plosone/s/preprints" >Preprints</a> </li> <li> <a href="/plosone/s/revising-your-manuscript" >Revising Your Manuscript</a> </li> <li> <a href="/plosone/s/submit-now" >Submit Now</a> </li> <li> <a href="https://collections.plos.org/s/calls-for-papers" >Calls for Papers</a> </li> </ul> </li> <li class="menu-section-header " id="policies"> <span class="menu-section-header-title"> Policies </span> <ul class="menu-section " id="policies-dropdown-list"> <li> <a href="/plosone/s/best-practices-in-research-reporting" >Best Practices in Research Reporting</a> </li> <li> <a href="/plosone/s/human-subjects-research" >Human Subjects Research</a> </li> <li> <a href="/plosone/s/animal-research" >Animal Research</a> </li> <li> <a href="/plosone/s/competing-interests" >Competing Interests</a> </li> <li> <a href="/plosone/s/disclosure-of-funding-sources" >Disclosure of Funding Sources</a> </li> <li> <a href="/plosone/s/licenses-and-copyright" >Licenses and Copyright</a> </li> <li> <a href="/plosone/s/data-availability" >Data Availability</a> </li> <li> <a href="/plosone/s/complementary-research" >Complementary Research</a> </li> <li> <a href="/plosone/s/materials-software-and-code-sharing" >Materials, Software and Code Sharing</a> </li> <li> <a href="/plosone/s/ethical-publishing-practice" >Ethical Publishing Practice</a> </li> <li> <a href="/plosone/s/authorship" >Authorship</a> </li> <li> <a href="/plosone/s/corrections-expressions-of-concern-and-retractions" >Corrections, Expressions of Concern, and Retractions</a> </li> </ul> </li> <li class="menu-section-header " id="manuscript-review-and-publication"> <span class="menu-section-header-title"> Manuscript Review and Publication </span> <ul class="menu-section " id="manuscript-review-and-publication-dropdown-list"> <li> <a href="/plosone/s/criteria-for-publication" >Criteria for Publication</a> </li> <li> <a href="/plosone/s/editorial-and-peer-review-process" >Editorial and Peer Review Process</a> </li> <li> <a href="https://plos.org/resources/editor-center" >Editor Center</a> </li> <li> <a href="/plosone/s/resources-for-editors" >Resources for Editors</a> </li> <li> <a href="/plosone/s/reviewer-guidelines" >Guidelines for Reviewers</a> </li> <li> <a href="/plosone/s/accepted-manuscripts" >Accepted Manuscripts</a> </li> <li> <a href="/plosone/s/comments" >Comments</a> </li> </ul> </li> </ul> <div class="calloutcontainer"> <h3 class="callout-headline">Submit Your Manuscript</h3> <div class="action-contain"> <p class="callout-content"> Discover a faster, simpler path to publishing in a high-quality journal. <em>PLOS ONE</em> promises fair, rigorous peer review, broad scope, and wide readership – a perfect fit for your research every time. </p> <p class="button-contain special"> <a class="button button-default" href="/plosone/static/publish"> Learn More </a> <a class="button-link" href="https://www.editorialmanager.com/pone/default.asp"> Submit Now </a> </p> </div>  </div> </div> </li> <li class="menu-section-header has-dropdown " id="about"> <span class="menu-section-header-title"> About </span> <ul class="menu-section dropdown " id="about-dropdown-list"> <li> <a href="/plosone/static/publish" >Why Publish with PLOS ONE</a> </li> <li> <a href="/plosone/s/journal-information" >Journal Information</a> </li> <li> <a href="/plosone/s/staff-editors" >Staff Editors</a> </li> <li> <a href="/plosone/static/editorial-board" >Editorial Board</a> </li> <li> <a href="/plosone/s/section-editors" >Section Editors</a> </li> <li> <a href="/plosone/s/advisory-groups" >Advisory Groups</a> </li> <li> <a href="/plosone/s/find-and-read-articles" >Find and Read Articles</a> </li> <li> <a href="/plosone/s/publishing-information" >Publishing Information</a> </li> <li> <a href="https://plos.org/publication-fees" >Publication Fees</a> </li> <li> <a href="https://plos.org/press-and-media" >Press and Media</a> </li> <li> <a href="/plosone/s/contact" >Contact</a> </li> </ul> </li> <li data-js-tooltip-hover="trigger" class="subject-area menu-section-header"> Browse </li> <script src="/resource/js/vendor/jquery.hoverIntent.js" type="text/javascript"></script> <script src="/resource/js/components/menu_drop.js" type="text/javascript"></script> <script src="/resource/js/components/hover_delay.js" type="text/javascript"></script> <li id="navsearch" class="head-search"> <form name="searchForm" action="/plosone/search" method="get"> <fieldset> <legend>Search</legend> <label for="search">Search</label> <div class="search-contain"> <input id="search" type="text" name="q" placeholder="SEARCH" required/> <button id="headerSearchButton" type="submit" aria-label="Submit search"> <i title="Submit search" class="search-icon"></i> </button> </div> </fieldset> <input type="hidden" name="filterJournals" value="PLoSONE"/> </form> <a id="advSearch" href="/plosone/search"> advanced search </a> <script src="/resource/js/components/placeholder_style.js" type="text/javascript"></script> </li> </ul> </section> </nav> </div> </header> <section id="taxonomyContainer"> <script src="/resource/js/taxonomy-browser.js" type="text/javascript"></script> <div id="taxonomy-browser" class="areas" data-search-url="/plosone/browse"> <div class="wrapper"> <div class="taxonomy-header"> Browse Subject Areas <div id="subjInfo">?</div> <div id="subjInfoText"> <p>Click through the PLOS taxonomy to find articles in your field.</p> <p>For more information about PLOS Subject Areas, click <a href="https://github.com/PLOS/plos-thesaurus/blob/master/README.md" target="_blank" title="Link opens in new window">here</a>. </p> </div> </div> <div class="levels"> <div class="levels-container cf"> <div class="levels-position"></div> </div> <a href="#" class="prev"></a> <a href="#" class="next active"></a> </div> </div> <div class="taxonomy-browser-border-bottom"></div> </div> </section> <main id="main-content"> <div class="set-grid"> <header class="title-block"> <script src="/resource/js/components/signposts.js" type="text/javascript"></script> <ul id="almSignposts" class="signposts"> <li id="loadingMetrics"> <p>Loading metrics</p> </li> </ul> <script type="text/template" id="signpostsGeneralErrorTemplate"> <li id="metricsError">Article metrics are unavailable at this time. Please try again later.</li> </script> <script type="text/template" id="signpostsNewArticleErrorTemplate"> <li></li><li></li><li id="tooSoon">Article metrics are unavailable for recently published articles.</li> </script> <script type="text/template" id="signpostsTemplate"> <li id="almSaves"> <%= s.numberFormat(saveCount, 0) %> <div class="tools" data-js-tooltip-hover="trigger"> <a class="metric-term" href="/plosone/article/metrics?id=10.1371/journal.pone.0026005#savedHeader">Save</a> <p class="saves-tip" data-js-tooltip-hover="target"><a href="/plosone/article/metrics?id=10.1371/journal.pone.0026005#savedHeader">Total Mendeley and Citeulike bookmarks.</a></p> </div> </li> <li id="almCitations"> <%= s.numberFormat(citationCount, 0) %> <div class="tools" data-js-tooltip-hover="trigger"> <a class="metric-term" href="/plosone/article/metrics?id=10.1371/journal.pone.0026005#citedHeader">Citation</a> <p class="citations-tip" data-js-tooltip-hover="target"><a href="/plosone/article/metrics?id=10.1371/journal.pone.0026005#citedHeader">Paper's citation count computed by Dimensions.</a></p> </div> </li> <li id="almViews"> <%= s.numberFormat(viewCount, 0) %> <div class="tools" data-js-tooltip-hover="trigger"> <a class="metric-term" href="/plosone/article/metrics?id=10.1371/journal.pone.0026005#viewedHeader">View</a> <p class="views-tip" data-js-tooltip-hover="target"><a href="/plosone/article/metrics?id=10.1371/journal.pone.0026005#viewedHeader">PLOS views and downloads.</a></p> </div> </li> <li id="almShares"> <%= s.numberFormat(shareCount, 0) %> <div class="tools" data-js-tooltip-hover="trigger"> <a class="metric-term" href="/plosone/article/metrics?id=10.1371/journal.pone.0026005#discussedHeader">Share</a> <p class="shares-tip" data-js-tooltip-hover="target"><a href="/plosone/article/metrics?id=10.1371/journal.pone.0026005#discussedHeader">Sum of Facebook, Twitter, Reddit and Wikipedia activity.</a></p> </div> </li> </script> <div class="article-meta"> <div class="classifications"> <p class="license-short" id="licenseShort">Open Access</p> <p class="peer-reviewed" id="peerReviewed">Peer-reviewed</p> <div class="article-type" > <p class="type-article" id="artType">Research Article</p> </div> </div> </div> <div class="article-title-etc"> <div class="title-authors"> <h1 id="artTitle"><?xml version="1.0" encoding="UTF-8"?>Declining Responsiveness of <i>Plasmodium falciparum</i> Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast</h1> <ul class="author-list clearfix" data-js-tooltip="tooltip_container" id="author-list"> <li data-js-tooltip="tooltip_trigger" > <a data-author-id="0" class="author-name" > Steffen Borrmann <span class="email"> </span>,</a> <div id="author-meta-0" class="author-info" data-js-tooltip="tooltip_target"> <p id="authCorresponding-0"> <span class="email">* E-mail:</span> <a href="mailto:sborrmann@kilifi.kemri-wellcome.org">sborrmann@kilifi.kemri-wellcome.org</a></p> <p id="authAffiliations-0"><span class="type">Affiliations</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya, Heidelberg University School of Medicine, Dept. of Infectious Diseases, Heidelberg, Germany </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose0"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" > <a data-author-id="1" class="author-name" > Philip Sasi,</a> <div id="author-meta-1" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-1"><span class="type">Affiliations</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya, Department of Clinical Pharmacology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose1"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" > <a data-author-id="2" class="author-name" > Leah Mwai,</a> <div id="author-meta-2" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-2"><span class="type">Affiliation</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose2"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" > <a data-author-id="3" class="author-name" > Mahfudh Bashraheil,</a> <div id="author-meta-3" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-3"><span class="type">Affiliation</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose3"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" > <a data-author-id="4" class="author-name" > Ahmed Abdallah,</a> <div id="author-meta-4" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-4"><span class="type">Affiliation</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose4"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" > <a data-author-id="5" class="author-name" > Steven Muriithi,</a> <div id="author-meta-5" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-5"><span class="type">Affiliation</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose5"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" > <a data-author-id="6" class="author-name" > Henrike Frühauf,</a> <div id="author-meta-6" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-6"><span class="type">Affiliations</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya, Heidelberg University School of Medicine, Dept. of Infectious Diseases, Heidelberg, Germany </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose6"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" > <a data-author-id="7" class="author-name" > Barbara Schaub,</a> <div id="author-meta-7" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-7"><span class="type">Affiliations</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya, Heidelberg University School of Medicine, Dept. of Infectious Diseases, Heidelberg, Germany </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose7"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" > <a data-author-id="8" class="author-name" > Johannes Pfeil,</a> <div id="author-meta-8" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-8"><span class="type">Affiliations</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya, Heidelberg University School of Medicine, Dept. of Infectious Diseases, Heidelberg, Germany </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose8"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" > <a data-author-id="9" class="author-name" > Judy Peshu,</a> <div id="author-meta-9" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-9"><span class="type">Affiliation</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose9"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" > <a data-author-id="10" class="author-name" > Warunee Hanpithakpong,</a> <div id="author-meta-10" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-10"><span class="type">Affiliation</span> Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose10"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" > <a data-author-id="11" class="author-name" > Anja Rippert,</a> <div id="author-meta-11" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-11"><span class="type">Affiliation</span> Heidelberg University School of Medicine, Dept. of Infectious Diseases, Heidelberg, Germany </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose11"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" > <a data-author-id="12" class="author-name" > Elizabeth Juma,</a> <div id="author-meta-12" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-12"><span class="type">Affiliation</span> Division of Malaria Control, Ministry of Health, Nairobi, Kenya </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose12"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" data-js-toggle="toggle_target" data-visibility= "none" > <a data-author-id="13" class="author-name" > Benjamin Tsofa,</a> <div id="author-meta-13" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-13"><span class="type">Affiliation</span> District Office, Ministry of Health, Kilifi, Kenya </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose13"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" data-js-toggle="toggle_target" data-visibility= "none" > <a data-author-id="14" class="author-name" > Moses Mosobo,</a> <div id="author-meta-14" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-14"><span class="type">Affiliation</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose14"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" data-js-toggle="toggle_target" data-visibility= "none" > <a data-author-id="15" class="author-name" > Brett Lowe,</a> <div id="author-meta-15" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-15"><span class="type">Affiliation</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose15"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" data-js-toggle="toggle_target" data-visibility= "none" > <a data-author-id="16" class="author-name" > Faith Osier,</a> <div id="author-meta-16" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-16"><span class="type">Affiliation</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose16"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" data-js-toggle="toggle_target" data-visibility= "none" > <a data-author-id="17" class="author-name" > Greg Fegan,</a> <div id="author-meta-17" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-17"><span class="type">Affiliation</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose17"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" data-js-toggle="toggle_target" data-visibility= "none" > <a data-author-id="18" class="author-name" > Niklas Lindegårdh,</a> <div id="author-meta-18" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-18"><span class="type">Affiliation</span> Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose18"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" data-js-toggle="toggle_target" data-visibility= "none" > <a data-author-id="19" class="author-name" > Alexis Nzila,</a> <div id="author-meta-19" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-19"><span class="type">Affiliation</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose19"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" data-js-toggle="toggle_target" data-visibility= "none" > <a data-author-id="20" class="author-name" > Norbert Peshu,</a> <div id="author-meta-20" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-20"><span class="type">Affiliation</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose20"> ⨯ </a> </div> </li> <li data-js-tooltip="tooltip_trigger" data-js-toggle="toggle_target" data-visibility= "none" > <a data-author-id="21" class="author-name" > Margaret Mackinnon,</a> <div id="author-meta-21" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-21"><span class="type">Affiliations</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, CCVTM, Oxford, United Kingdom </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose21"> ⨯ </a> </div> </li> <li data-js-toggle="toggle_add"> [ ... ],</li> <li data-js-tooltip="tooltip_trigger" > <a data-author-id="22" class="author-name" > Kevin Marsh</a> <div id="author-meta-22" class="author-info" data-js-tooltip="tooltip_target"> <p id="authAffiliations-22"><span class="type">Affiliations</span> Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, CCVTM, Oxford, United Kingdom </p> <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose22"> ⨯ </a> </div> </li> <li data-js-toggle="toggle_trigger" > <a class="more-authors active" id="authors-show">[ view all ]</a> </li> <li data-js-toggle="toggle_trigger" data-visibility="none"> <a class="author-less" id="author-hide">[ view less ]</a> </li> </ul> <script src="/resource/js/components/tooltip.js" type="text/javascript"></script> </div> <div id="floatTitleTop" data-js-floater="title_author" class="float-title" role="presentation"> <div class="set-grid"> <div class="float-title-inner"> <h1><?xml version="1.0" encoding="UTF-8"?>Declining Responsiveness of <i>Plasmodium falciparum</i> Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast</h1> <ul id="floatAuthorList" data-js-floater="floated_authors"> <li data-float-index="1">Steffen Borrmann,  </li> <li data-float-index="2">Philip Sasi,  </li> <li data-float-index="3">Leah Mwai,  </li> <li data-float-index="4">Mahfudh Bashraheil,  </li> <li data-float-index="5">Ahmed Abdallah,  </li> <li data-float-index="6">Steven Muriithi,  </li> <li data-float-index="7">Henrike Frühauf,  </li> <li data-float-index="8">Barbara Schaub,  </li> <li data-float-index="9">Johannes Pfeil,  </li> <li data-float-index="10">Judy Peshu </ul> </div> <div class="logo-close" id="titleTopCloser"> <img src="/resource/img/logo-plos.png" style="height: 2em" alt="PLOS" /> <div class="close-floater" title="close">x</div> </div> </div> </div> <ul class="date-doi"> <li id="artPubDate">Published: November 10, 2011</li> <li id="artDoi"> <a href="https://doi.org/10.1371/journal.pone.0026005">https://doi.org/10.1371/journal.pone.0026005</a> </li> <li class="flex-spacer"></li> </ul> </div> <div> </div> </header> <section class="article-body"> <ul class="article-tabs"> <li class="tab-title active" id="tabArticle"> <a href="/plosone/article?id=10.1371/journal.pone.0026005" class="article-tab-1">Article</a> </li> <li class="tab-title " id="tabAuthors"> <a href="/plosone/article/authors?id=10.1371/journal.pone.0026005" class="article-tab-2">Authors</a> </li> <li class="tab-title " id="tabMetrics"> <a href="/plosone/article/metrics?id=10.1371/journal.pone.0026005" class="article-tab-3">Metrics</a> </li> <li class="tab-title " id="tabComments"> <a href="/plosone/article/comments?id=10.1371/journal.pone.0026005" class="article-tab-4">Comments</a> </li> <li class="tab-title" id="tabRelated"> <a class="article-tab-5" id="tabRelated-link">Media Coverage</a> <script>$(document).ready(function() { $.getMediaLink("10.1371/journal.pone.0026005").then(function (url) { $("#tabRelated-link").attr("href", url) } ) })</script> </li> </ul> <div class="article-container"> <div id="nav-article"> <ul class="nav-secondary"> <li class="nav-comments" id="nav-comments"> <a href="article/comments?id=10.1371/journal.pone.0026005">Reader Comments</a> </li> <li id="nav-figures"><a href="#" data-doi="10.1371/journal.pone.0026005">Figures</a></li> </ul> <div id="nav-data-linking" data-data-url=""> </div> </div> <script src="/resource/js/components/scroll.js" type="text/javascript"></script> <script src="/resource/js/components/nav_builder.js" type="text/javascript"></script> <script src="/resource/js/components/floating_nav.js" type="text/javascript"></script> <div id="figure-lightbox-container"></div> <script id="figure-lightbox-template" type="text/template"> <div id="figure-lightbox" class="reveal-modal full" data-reveal aria-hidden="true" role="dialog"> <div class="lb-header"> <h1 id="lb-title"><%= articleTitle %></h1> <div id="lb-authors"> <span>Steffen Borrmann</span> <span>Philip Sasi</span> <a class="more-authors" href="/plosone/article/authors?id=10.1371/journal.pone.0026005">...</a> <span>Kevin Marsh</span> </div> <div class="lb-close" title="close"> </div> </div> <div class="img-container"> <div class="loader"> <i class="fa-spinner"></i> </div> <img class="main-lightbox-image" src=""/> <aside id="figures-list"> <% figureList.each(function (ix, figure) { %> <div class="change-img" data-doi="<%= figure.getAttribute('data-doi') %>"> <img class="aside-figure" src="/plosone/article/figure/image?size=inline&id=<%= figure.getAttribute('data-doi') %>" /> </div> <% }) %> <div class="dummy-figure"> </div> </aside> </div> <div id="lightbox-footer"> <div id="btns-container" class="lightbox-row <% if(figureList.length <= 1) { print('one-figure-only') } %>"> <div class="fig-btns-container reset-zoom-wrapper left"> <span class="fig-btn reset-zoom-btn">Reset zoom</span> </div> <div class="zoom-slider-container"> <div class="range-slider-container"> <span id="lb-zoom-min"></span> <div class="range-slider round" data-slider data-options="start: 20; end: 200; initial: 20;"> <span class="range-slider-handle" role="slider" tabindex="0"></span> <span class="range-slider-active-segment"></span> <input type="hidden"> </div> <span id="lb-zoom-max"></span> </div> </div> <% if(figureList.length > 1) { %> <div class="fig-btns-container"> <span class="fig-btn all-fig-btn"><i class="icon icon-all"></i> All Figures</span> <span class="fig-btn next-fig-btn"><i class="icon icon-next"></i> Next</span> <span class="fig-btn prev-fig-btn"><i class="icon icon-prev"></i> Previous</span> </div> <% } %> </div> <div id="image-context"> </div> </div> </div> </script> <script id="image-context-template" type="text/template"> <div class="footer-text"> <div id="figure-description-wrapper"> <div id="view-more-wrapper" style="<% descriptionExpanded? print('display:none;') : '' %>"> <span id="figure-title"><%= title %></span> <p id="figure-description"> <%= description %>   </p> <span id="view-more">show more<i class="icon-arrow-right"></i></span> </div> <div id="view-less-wrapper" style="<% descriptionExpanded? print('display:inline-block;') : '' %>" > <span id="figure-title"><%= title %></span> <p id="full-figure-description"> <%= description %>   <span id="view-less">show less<i class="icon-arrow-left"></i></span> </p> </div> </div> </div> <div id="show-context-container"> <a class="btn show-context" href="<%= showInContext(strippedDoi) %>">Show in Context</a> </div> <div id="download-buttons"> <h3>Download:</h3> <div class="item"> <a href="/plosone/article/figure/image?size=original&download=&id=<%= doi %>" title="original image"> <span class="download-btn">TIFF</span> </a> <span class="file-size"><%= fileSizes.original %></span> </div> <div class="item"> <a href="/plosone/article/figure/image?size=large&download=&id=<%= doi %>" title="large image"> <span class="download-btn">PNG</span> </a> <span class="file-size"><%= fileSizes.large %></span> </div> <div class="item"> <a href="/plosone/article/figure/powerpoint?id=<%= doi %>" title="PowerPoint slide"> <span class="download-btn">PPT</span> </a> </div> </div> </script> <div class="article-content"> <div id="figure-carousel-section"> <h2>Figures</h2> <div id="figure-carousel"> <div class="carousel-wrapper"> <div class="slider"> <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0026005.g001"> <img src="/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0026005.g001" loading="lazy" alt="Figure 1" /> </div> <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0026005.t001"> <img src="/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0026005.t001" loading="lazy" alt="Table 1" /> </div> <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0026005.t002"> <img src="/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0026005.t002" loading="lazy" alt="Table 2" /> </div> <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0026005.g002"> <img src="/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0026005.g002" loading="lazy" alt="Figure 2" /> </div> <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0026005.g003"> <img src="/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0026005.g003" loading="lazy" alt="Figure 3" /> </div> <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0026005.t003"> <img src="/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0026005.t003" loading="lazy" alt="Table 3" /> </div> </div> </div> <div class="carousel-control"> <span class="button previous"></span> <span class="button next"></span> </div> <div class="carousel-page-buttons"> </div> </div> </div> <script src="/resource/js/vendor/jquery.touchswipe.js" type="text/javascript"></script> <script src="/resource/js/components/figure_carousel.js" type="text/javascript"></script> <script src="/resource/js/vendor/jquery.dotdotdot.js" type="text/javascript"></script> <div class="article-text" id="artText"> <div xmlns:plos="http://plos.org" class="abstract toc-section abstract-type-"><a id="abstract0" name="abstract0" data-toc="abstract0" class="link-target" title="Abstract"></a><h2>Abstract</h2><div class="abstract-content"> <div id="section1" class="section toc-section"><a id="" name="" class="link-target" title="Background"></a> <h3>Background</h3> <a id="article1.front1.article-meta1.abstract1.sec1.p1" name="article1.front1.article-meta1.abstract1.sec1.p1" class="link-target"></a><p>The emergence of artemisinin-resistant <em>P. falciparum</em> malaria in South-East Asia highlights the need for continued global surveillance of the efficacy of artemisinin-based combination therapies.</p> </div> <div id="section2" class="section toc-section"><a id="" name="" class="link-target" title="Methods"></a> <h3>Methods</h3> <a id="article1.front1.article-meta1.abstract1.sec2.p1" name="article1.front1.article-meta1.abstract1.sec2.p1" class="link-target"></a><p>On the Kenyan coast we studied the treatment responses in 474 children 6–59 months old with uncomplicated <em>P. falciparum</em> malaria in a randomized controlled trial of dihydroartemisinin-piperaquine <em>vs.</em> artemether-lumefantrine from 2005 to 2008. (ISRCTN88705995)</p> </div> <div id="section3" class="section toc-section"><a id="" name="" class="link-target" title="Results"></a> <h3>Results</h3> <a id="article1.front1.article-meta1.abstract1.sec3.p1" name="article1.front1.article-meta1.abstract1.sec3.p1" class="link-target"></a><p>The proportion of patients with residual parasitemia on day 1 rose from 55% in 2005–2006 to 87% in 2007–2008 (odds ratio, 5.4, 95%CI, 2.7–11.1; <em>P</em><0.001) and from 81% to 95% (OR, 4.1, 95%CI, 1.7–9.9; <em>P</em> = 0.002) in the DHA-PPQ and AM-LM groups, respectively. In parallel, Kaplan-Meier estimated risks of apparent recrudescent infection by day 84 increased from 7% to 14% (<em>P</em> = 0.1) and from 6% to 15% (<em>P</em> = 0.05) with DHA-PPQ and AM-LM, respectively. Coinciding with decreasing transmission in the study area, clinical tolerance to parasitemia (defined as absence of fever) declined between 2005–2006 and 2007–2008 (OR body temperature >37.5°C, 2.8, 1.9–4.1; <em>P</em><0.001). Neither <em>in vitro</em> sensitivity of parasites to DHA nor levels of antibodies against parasite extract accounted for parasite clearance rates or changes thereof.</p> </div> <div id="section4" class="section toc-section"><a id="" name="" class="link-target" title="Conclusions"></a> <h3>Conclusions</h3> <a id="article1.front1.article-meta1.abstract1.sec4.p1" name="article1.front1.article-meta1.abstract1.sec4.p1" class="link-target"></a><p>The significant, albeit small, decline through time of parasitological response rates to treatment with ACTs may be due to the emergence of parasites with reduced drug sensitivity, to the coincident reduction in population-level clinical immunity, or both. Maintaining the efficacy of artemisinin-based therapy in Africa would benefit from a better understanding of the mechanisms underlying reduced parasite clearance rates.</p> </div> <div id="section5" class="section toc-section"><a id="" name="" class="link-target" title="Trial Registration"></a> <h3>Trial Registration</h3> <a id="article1.front1.article-meta1.abstract1.sec5.p1" name="article1.front1.article-meta1.abstract1.sec5.p1" class="link-target"></a><p>Controlled-Trials.com <a href="http://www.controlled-trials.com/ISRCTN88705995">ISRCTN88705995</a></p> </div> </div></div> <div xmlns:plos="http://plos.org" class="articleinfo"><p><strong>Citation: </strong>Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, et al. (2011) Declining Responsiveness of <em>Plasmodium falciparum</em> Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast. PLoS ONE 6(11): e26005. https://doi.org/10.1371/journal.pone.0026005</p><p><strong>Editor: </strong>Ivo Mueller, Walter & Eliza Hall Institute, Australia</p><p><strong>Received: </strong>July 8, 2011; <strong>Accepted: </strong>September 15, 2011; <strong>Published: </strong> November 10, 2011</p><p><strong>Copyright: </strong> © 2011 Borrmann et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p><p><strong>Funding: </strong>This study was supported by DFG (SFB 544, Junior Group A7) and MMV grants to SB, and by European Developing Countries Clinical Trials Partnership (EDCTP to LM and AN), and by The Wellcome Trust (WT077092). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p><p><strong>Competing interests: </strong> The authors have declared that no competing interests exist.</p></div> <div xmlns:plos="http://plos.org" id="section1" class="section toc-section"><a id="s1" name="s1" data-toc="s1" class="link-target" title="Introduction"></a><h2>Introduction</h2><a id="article1.body1.sec1.p1" name="article1.body1.sec1.p1" class="link-target"></a><p>Over the last few decades the global spread of parasite resistance to key antimalarial drugs such as chloroquine and pyrimethamine has been a challenge for malaria control programs based primarily on prompt and effective treatment <a href="#pone.0026005-Trape1" class="ref-tip">[1]</a>–<a href="#pone.0026005-Korenromp1" class="ref-tip">[3]</a>. The introduction of highly efficacious artemisinin-based combination treatments (ACT) as first-line treatment in most malaria endemic countries has contributed to recent notable reversals of trends in childhood morbidity and mortality <a href="#pone.0026005-Bhattarai1" class="ref-tip">[4]</a>, <a href="#pone.0026005-Barnes1" class="ref-tip">[5]</a>. Because of the prominent value of ACTs in current malaria control programs, the emergence of parasite resistance to artemisinins and the associated compromised efficacy of ACTs would pose a major public health problem. The recently reported emergence of artemisinin-resistant malaria characterized by slow initial parasite clearance and high rates of recrudescent infections in Western Cambodia and, possibly, other countries South East Asia is therefore of great concern <a href="#pone.0026005-Dondorp1" class="ref-tip">[6]</a>–<a href="#pone.0026005-Dondorp2" class="ref-tip">[9]</a>.</p> <a id="article1.body1.sec1.p2" name="article1.body1.sec1.p2" class="link-target"></a><p>Using data from a randomized controlled clinical trial, we performed a post-hoc analysis of the <em>in vivo</em> response to two ACT regimens, namely dihydroartemisinin-piperaquine (DHA-PPQ) and artemether-lumefantrine (AM-LM) over time. The study was conducted from 2005 to 2008, coinciding with the introduction of artemether-lumefantrine (Coartem™) as the exclusive first-line treatment for all presumptive cases of uncomplicated <em>P. falciparum</em> malaria in Kilifi District, Coast Province, Kenya in 2006.</p> </div> <div xmlns:plos="http://plos.org" id="section2" class="section toc-section"><a id="s2" name="s2" data-toc="s2" class="link-target" title="Methods"></a><h2>Methods</h2> <div id="section1" class="section toc-section"><a id="s2a" name="s2a" class="link-target" title="Study site"></a> <h3>Study site</h3> <a id="article1.body1.sec2.sec1.p1" name="article1.body1.sec2.sec1.p1" class="link-target"></a><p>The study was conducted at the Pingilikani study site <a href="#pone.0026005-Sasi1" class="ref-tip">[10]</a>, <a href="#pone.0026005-Olotu1" class="ref-tip">[11]</a>. Malaria transmission in the area is perennial but with peaks trailing typically two annual rainy seasons <a href="#pone.0026005-OMeara1" class="ref-tip">[12]</a>. The parasite positivity rate in outpatients has declined precipitously from 2003 to 2005 (own unpublished data and <a href="#pone.0026005-OMeara1" class="ref-tip">[12]</a>). The study was approved by the National KEMRI Ethical Review Committee, Kenya; the Oxford Tropical Research Ethics Committee, UK; and the Ethics Committee, Heidelberg University School of Medicine, Germany. The protocol for this trial and supporting CONSORT checklist are available as supporting information; see <a href="#pone.0026005.s006">Checklist S1</a> and <a href="#pone.0026005.s005">Protocol S1</a>.</p> </div> <div id="section2" class="section toc-section"><a id="s2b" name="s2b" class="link-target" title="Study design and sample size"></a> <h3>Study design and sample size</h3> <a id="article1.body1.sec2.sec2.p1" name="article1.body1.sec2.sec2.p1" class="link-target"></a><p>This is a detailed analysis of treatment response rates according to year of enrollment in a non-inferiority randomized controlled trial that evaluated the efficacy of DHA-PPQ vs. AM-LM in the treatment of children with uncomplicated <em>P. falciparum</em> malaria in Kilifi, Kenya (Controlled Trials Registry number, ISRCTN88705995). The primary efficacy endpoint was the 28-day cure rate adjusted for reinfection (defined as clearance of asexual parasites by day 7 and absence of PCR-confirmed recrudescence of primary infection). Assuming a cure rate of 95% with AM-LM and a 5% drop-out rate, we calculated that 250 patients per arm would provide 80% power to test a 5% non-inferiority margin with a 97.5% one-sided confidence interval.</p> </div> <div id="section3" class="section toc-section"><a id="s2c" name="s2c" class="link-target" title="Enrollment of patients"></a> <h3>Enrollment of patients</h3> <a id="article1.body1.sec2.sec3.p1" name="article1.body1.sec2.sec3.p1" class="link-target"></a><p>We enrolled pediatric outpatients aged 6–59 months with uncomplicated <em>P. falciparum</em> malaria who met the following selection criteria: reported or documented fever ≥37.5°C, <em>P. falciparum</em> mono-infection, microscopically determined peripheral asexual parasite density of 2,000–200,000/µL, body weight >5 kg and signed informed consent by parent or legal guardian. We excluded patients with known allergies, severe malaria or danger signs <a href="#pone.0026005-WHO1" class="ref-tip">[13]</a>, participation in an investigational drug study within previous 30 days, ECG abnormalities requiring urgent management, other relevant clinical conditions or severe acute malnutrition. A randomization list was generated by an independent off site contract research organization (CRO). Sealed envelopes containing treatment allocation were used to randomize eligible patients to treatment with DHA-PPQ or AM-LM. The randomization ratio was 2∶1 (DHA-PPQ∶AM-LM) for patients enrolled in 2005–2006 and reversed to 1∶2 in 2007–2008 to accommodate a multicenter trial analysis <a href="#pone.0026005-Bassat1" class="ref-tip">[14]</a> that required 2∶1 randomization for patients enrolled in 2005–2006 while achieving an overall balanced 1∶1 randomization.</p> </div> <div id="section4" class="section toc-section"><a id="s2d" name="s2d" class="link-target" title="Study drug and administration"></a> <h3>Study drug and administration</h3> <a id="article1.body1.sec2.sec4.p1" name="article1.body1.sec2.sec4.p1" class="link-target"></a><p>Study drugs were administered orally with food or drinks under direct supervision. For children <2 years old tablets were crushed, mixed with 50 ml water, and administered as slurry. DHA-PPQ was given 24-hourly for 3 days at single target doses of 2.25 mg of DHA/kg body weight and 18 mg of PPQ/kg (formulated as pediatric or adult strength fixed dose combinations of 20/160 mg and 40/320 mg, respectively; Eurartesim™, SigmaTau, Italy). Doses were rounded up to the nearest half tablet. AM-LM was administered as whole tablets according to the manufacturer's instructions in 6 doses over 3 days (0, 8, 24, 36, 48, and 60 hours) at mean target doses of 2 mg of AM/kg and 12 mg of LM/kg (Coartem™, Novartis, Switzerland). Participants who vomited or rejected the study drug within 30 min received a second full dose, and those who vomited or rejected the study drug after 30 min but within 1 h received a second half dose. Vomiting or rejecting the second dose led to withdrawal from the study and administration of rescue medication. Stability tests that were performed by the drug manufacturers upon request confirmed that titer and degradation products of study drugs were still within stringent regulatory specifications in 2009, >10 months after completion of the study.</p> </div> <div id="section5" class="section toc-section"><a id="s2e" name="s2e" class="link-target" title="Study flow and clinical procedures"></a> <h3>Study flow and clinical procedures</h3> <a id="article1.body1.sec2.sec5.p1" name="article1.body1.sec2.sec5.p1" class="link-target"></a><p>During the 3-day treatment phase, patients were admitted to the KEMRI research ward in Pingilikani to ensure strict adhesion to dosing intervals. Patients were seen by study clinicians on days 0, 1, 2 and 3 and then for weekly follow-up visits until day 63 and finally on day 84 for collecting medical history, vital signs, malaria blood smears, and adverse events. Giemsa-stained malaria slides were read blinded by the same microscopist throughout the study according to KEMRI standard operating procedures.</p> </div> <div id="section6" class="section toc-section"><a id="s2f" name="s2f" class="link-target" title="Genotyping"></a> <h3>Genotyping</h3> <a id="article1.body1.sec2.sec6.p1" name="article1.body1.sec2.sec6.p1" class="link-target"></a><p>To distinguish recrudescent from new infections and to determine the multiplicity of infection (MOI) index, matched pairs of parasite isolates obtained at baseline and recurrence were compared using RFLP-based genotyping analysis of repeat length polymorphisms in the <em>MSP2</em> gene (PFB0300c) <a href="#pone.0026005-Felger1" class="ref-tip">[15]</a>. Results were verified by genotyping additional loci (<em>MSP1</em> and <em>GLURP</em>) or semi-automated capillary electrophoresis-based analysis of fluorescence-labeled <em>MSP2</em> PCR products <a href="#pone.0026005-Falk1" class="ref-tip">[16]</a>. Recrudescence was defined as persistence of at least one baseline clone. Genomic copy number variants at the <em>MDR1</em> locus (PFE1150w) were determined by quantitative real-time PCR using the β-tubulin gene (PF10_0084) as internal control and 3D7 (1 copy) and Dd2 (2 copies) reference strains for calibration <a href="#pone.0026005-Price1" class="ref-tip">[17]</a>.</p> </div> <div id="section7" class="section toc-section"><a id="s2g" name="s2g" class="link-target" title="Pharmacokinetic measurements"></a> <h3>Pharmacokinetic measurements</h3> <a id="article1.body1.sec2.sec7.p1" name="article1.body1.sec2.sec7.p1" class="link-target"></a><p>Serum samples collected on day 7 were analyzed for LM by solid-phase extraction and liquid chromatography (LC) with UV detection as described previously <a href="#pone.0026005-Annerberg1" class="ref-tip">[18]</a>, PPQ and its stable isotope labeled internal standard were analyzed using high throughput LC-MS/MS on an ABI 5000 triple quadrupole mass spectrometer (Applied Biosystems/MDS SCIEX, Foster City, USA), with a TurboV ionization source interface operated in the positive ion mode <a href="#pone.0026005-Lindegardh1" class="ref-tip">[19]</a>. The lower limit of quantification (LLOQ) for PPQ and LM were set to 1.5 ng/ml and 50 ng/ml, respectively.</p> </div> <div id="section8" class="section toc-section"><a id="s2h" name="s2h" class="link-target" title="Parasite adaptation and chemosensitivity testing"></a> <h3>Parasite adaptation and chemosensitivity testing</h3> <a id="article1.body1.sec2.sec8.p1" name="article1.body1.sec2.sec8.p1" class="link-target"></a><p>Parasite isolates were adapted to <em>in vitro</em> culture according to standard protocols <a href="#pone.0026005-Sasi1" class="ref-tip">[10]</a>. We determined the concentrations of DHA, PPQ and LM required to inhibit the <em>in vitro</em> growth of parasite isolates by 50% (IC<sub>50</sub>) compared to unexposed controls using regression analysis of the dose-response curves from duplicate <sup>3</sup>H-hypoxanthine uptake 72-hour exposure experiments <a href="#pone.0026005-Sasi1" class="ref-tip">[10]</a>. Two reference strains (V1S, a multidrug-resistant strain, and 3D7, a drug-sensitive strain) were used as controls.</p> </div> <div id="section9" class="section toc-section"><a id="s2i" name="s2i" class="link-target" title="Anti-parasitic antibody responses"></a> <h3>Anti-parasitic antibody responses</h3> <a id="article1.body1.sec2.sec9.p1" name="article1.body1.sec2.sec9.p1" class="link-target"></a><p>We used an established ELISA protocol to measure concentrations of antibodies against parasite schizont extract (A4 strain) <a href="#pone.0026005-Osier1" class="ref-tip">[20]</a>. Hyper-immune sera from Kenyan donors and sera from unexposed European individuals were run in duplicate on each plate as positive and negative controls, respectively.</p> </div> <div id="section10" class="section toc-section"><a id="s2j" name="s2j" class="link-target" title="Statistical analysis"></a> <h3>Statistical analysis</h3> <a id="article1.body1.sec2.sec10.p1" name="article1.body1.sec2.sec10.p1" class="link-target"></a><p>As a measure of drug efficacy, we computed the day 1 parasite reduction ratio (PRR<sub>D1</sub>) as the log<sub>10</sub> quotient of baseline and day 1 parasitemias (after setting parasitemias below the microscopic detection threshold on day 1 to 10/µL). We also analyzed the probability that parasites were detected by microscopy or not on day 1 by binomial logistic regression for the influences of period of enrolment (2005–2006 vs. 2007–2008), log<sub>10</sub> baseline parasitemia, treatment (AM-LM vs. DHA-PPQ), dose per body weight, patient age, number of previous malaria episodes and anti-schizont antibody levels fitting each of these separately in univariable analyses and then combined in one multivariable analysis if they remained significant at the <em>P</em>≤0.2 level. Similarly, we analyzed percentage reductions of parasite densities from baseline calculated by dividing baseline densities with densities at day 1 or 2 multiplied by 100. Parasite and fever clearance times were estimated by parametric survival analysis of the time from baseline to the first of two consecutive negative blood smears or temperature measurements <37.5°C, respectively. Risk of recrudescent primary or secondary (re-) infections was assessed by the Kaplan-Meier (KM) method for survival data. For these analyses, patients who did not meet a study endpoint (either absence or recurrence of parasitemia from day 7 to day 84) were censored at the last visit before dropout (<a href="#pone-0026005-g001">Fig. 1</a>). Cox proportional hazards model was used to estimate hazards ratios (HR). Data on previous malaria episodes were obtained by matching subjects to a passive outpatient surveillance system operated at Pingilikani since 2003. Other traits were analyzed by either <em>t</em>-test or linear regression assuming normal distributions, by Kruskal-Wallis equality-of-populations rank test assuming non-parametric distribution or, if proportion or count data, by Fisher's exact test and Poisson logistic regression, respectively. All analyses were performed with Stata 11.0 (StataCorp, College Station, TX).</p> <a class="link-target" id="pone-0026005-g001" name="pone-0026005-g001"></a><div class="figure" data-doi="10.1371/journal.pone.0026005.g001"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&id=10.1371/journal.pone.0026005.g001" data-doi="10.1371/journal.pone.0026005" data-uri="10.1371/journal.pone.0026005.g001"><img src="article/figure/image?size=inline&id=10.1371/journal.pone.0026005.g001" alt="thumbnail" class="thumbnail" loading="lazy"></a><div class="expand"></div></div><div class="figure-inline-download"> Download: <ul><li><a href="article/figure/powerpoint?id=10.1371/journal.pone.0026005.g001"><div class="definition-label">PPT</div><div class="definition-description">PowerPoint slide</div></a></li><li><a href="article/figure/image?download&size=large&id=10.1371/journal.pone.0026005.g001"><div class="definition-label">PNG</div><div class="definition-description">larger image</div></a></li><li><a href="article/figure/image?download&size=original&id=10.1371/journal.pone.0026005.g001"><div class="definition-label">TIFF</div><div class="definition-description">original image</div></a></li></ul></div><div class="figcaption"><span>Figure 1. </span> Study profile.</div><p class="caption_target"></p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0026005.g001"> https://doi.org/10.1371/journal.pone.0026005.g001</a></p></div></div> </div> <div xmlns:plos="http://plos.org" id="section3" class="section toc-section"><a id="s3" name="s3" data-toc="s3" class="link-target" title="Results"></a><h2>Results</h2> <div id="section1" class="section toc-section"><a id="s3a" name="s3a" class="link-target" title="Study cohort"></a> <h3>Study cohort</h3> <a id="article1.body1.sec3.sec1.p1" name="article1.body1.sec3.sec1.p1" class="link-target"></a><p>Between September 2005 and April 2008 we enrolled 474 patients. Enrollment was temporarily suspended between July 2006 and March 2007. 450 patients received a full treatment course (<a href="#pone-0026005-g001">Fig. 1</a>). Repeated vomiting occurred in 7/233 (3%) and 4/241 (2%) patients in the DHA-PPQ and AM-LM groups, respectively (<em>P</em>>0.3) (<a href="#pone-0026005-g001">Fig. 1</a>). Early treatment failure due to severe malaria occurred in 3 patients receiving DHA-PPQ and 1 patient receiving AM-LM group (<a href="#pone-0026005-g001">Fig. 1</a>). <a href="#pone-0026005-t001">Table 1</a> details baseline characteristics of patients by treatment group and period of enrollment. In a pooled analysis of both treatment groups, patients enrolled in 2007–2008 were between 5 to 7 months older (<em>P</em><0.05), weighed about 1 kg more (<em>P</em><0.05), had higher parasitemias (<em>P</em> = 0.03) and axillary temperatures (<em>P</em><0.001), increased number of parasite clones as determined by <em>MSP2</em> allele typing (<em>P</em><0.01) and higher hemoglobin concentration (<em>P</em> = 0.03 in AM-LM group only). Other characteristics, notably platelet concentrations <a href="#pone.0026005-McMorran1" class="ref-tip">[21]</a>, were similar between enrollment periods.</p> <a class="link-target" id="pone-0026005-t001" name="pone-0026005-t001"></a><div class="figure" data-doi="10.1371/journal.pone.0026005.t001"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&id=10.1371/journal.pone.0026005.t001" data-doi="10.1371/journal.pone.0026005" data-uri="10.1371/journal.pone.0026005.t001"><img src="article/figure/image?size=inline&id=10.1371/journal.pone.0026005.t001" alt="thumbnail" class="thumbnail" loading="lazy"></a><div class="expand"></div></div><div class="figure-inline-download"> Download: <ul><li><a href="article/figure/powerpoint?id=10.1371/journal.pone.0026005.t001"><div class="definition-label">PPT</div><div class="definition-description">PowerPoint slide</div></a></li><li><a href="article/figure/image?download&size=large&id=10.1371/journal.pone.0026005.t001"><div class="definition-label">PNG</div><div class="definition-description">larger image</div></a></li><li><a href="article/figure/image?download&size=original&id=10.1371/journal.pone.0026005.t001"><div class="definition-label">TIFF</div><div class="definition-description">original image</div></a></li></ul></div><div class="figcaption"><span>Table 1. </span> Baseline characteristics of patients.</div><p class="caption_target"></p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0026005.t001"> https://doi.org/10.1371/journal.pone.0026005.t001</a></p></div></div> <div id="section2" class="section toc-section"><a id="s3b" name="s3b" class="link-target" title="Parasitological and clinical treatment responses"></a> <h3>Parasitological and clinical treatment responses</h3> <a id="article1.body1.sec3.sec2.p1" name="article1.body1.sec3.sec2.p1" class="link-target"></a><p>Treatment with DHA-PPQ cleared parasites faster than AM-LM (means of 41 hours <em>vs.</em> 48 hours, respectively; <em>P</em><0.001) resulting also in prompter clearance of fever (means of 27 hours <em>vs.</em> 30 hours respectively; <em>P</em><0.001). By day 28, Kaplan-Meier (KM)-estimated PCR-adjusted rates of recrudescent primary infections were 1% (95% CI, 0–4) and 1% (95% CI, 0–4) in the DHA-PPQ and AM-LM groups, respectively (HR = 0.9; 95% CI, 0.2–4.7). By day 84 we noted considerably higher PCR-adjusted recrudescence rates with both DHA-PPQ (10%; 95% CI, 6–15) and AM-LM (13%; 95% CI, 8–18) (HR, 1.3; 95% CI, 0.7–2.4). By day 84 reinfections occurred in 39% (KM 95% CI, 33–47) and 42% (KM 95% CI, 35–49) of children treated with DHA-PPQ and AM-LM groups, respectively (<em>P</em> = 0.7), with no difference in median time to reinfection (<a href="#pone-0026005-t002">Table 2</a>).</p> <a class="link-target" id="pone-0026005-t002" name="pone-0026005-t002"></a><div class="figure" data-doi="10.1371/journal.pone.0026005.t002"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&id=10.1371/journal.pone.0026005.t002" data-doi="10.1371/journal.pone.0026005" data-uri="10.1371/journal.pone.0026005.t002"><img src="article/figure/image?size=inline&id=10.1371/journal.pone.0026005.t002" alt="thumbnail" class="thumbnail" loading="lazy"></a><div class="expand"></div></div><div class="figure-inline-download"> Download: <ul><li><a href="article/figure/powerpoint?id=10.1371/journal.pone.0026005.t002"><div class="definition-label">PPT</div><div class="definition-description">PowerPoint slide</div></a></li><li><a href="article/figure/image?download&size=large&id=10.1371/journal.pone.0026005.t002"><div class="definition-label">PNG</div><div class="definition-description">larger image</div></a></li><li><a href="article/figure/image?download&size=original&id=10.1371/journal.pone.0026005.t002"><div class="definition-label">TIFF</div><div class="definition-description">original image</div></a></li></ul></div><div class="figcaption"><span>Table 2. </span> Treatment responses in pediatric patients treated with artemisinin-based combination chemotherapies.</div><p class="caption_target"></p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0026005.t002"> https://doi.org/10.1371/journal.pone.0026005.t002</a></p></div><a id="article1.body1.sec3.sec2.p2" name="article1.body1.sec3.sec2.p2" class="link-target"></a><p>When comparing treatment responses in patients enrolled in 2005–2006 <em>vs.</em> 2007–2008 in a post-hoc analysis we observed a striking increase in the proportion of children with detectable parasitemia one day after initiation of treatment (day 1 parasite prevalence rate, PPR<sub>D1</sub>; <a href="#pone-0026005-t002">Table 2</a>). This proportion rose from 55% to 87% (odds ratio, 5.4, 95% CI, 2.7–11.1; <em>P</em><0.001) in the DHA-PPQ group and from 81% to 95% (OR, 4.1, 95% CI, 1.7–9.9; <em>P</em> = 0.002) in the AM-LM group. Median day 1 parasite reduction ratio in the DHA-PPQ group dropped by 78% (4.6-fold lower) and in the AM-LM group by 69% (3.2-fold lower) between the 2005–2006 and 2007–2008 enrollment periods (<em>P</em><0.001 by logistic regression) and the same effect was observed within age groups (<a href="#pone-0026005-g002">Fig. 2</a> and <a href="#pone-0026005-t002">Table 2</a>). These changes in initial parasite responses were accompanied by significantly prolonged mean times to fever clearance (<a href="#pone-0026005-t002">Table 2</a>; <em>P</em><0.002) and a more than two fold risk of apparent recrudescent primary infections by day 84 (<a href="#pone-0026005-t002">Table 2</a>; <em>P</em> = 0.01 when pooling data across treatment groups). Reinfection rates by day 84, which could have confounded PCR-based classification of recrudescent primary infections <a href="#pone.0026005-Borrmann1" class="ref-tip">[22]</a>, were high but did not change over time (<em>P</em>>0.2; <a href="#pone-0026005-t002">Table 2</a>). Gametocyte carrier rates during follow-up were low and independent of study period (<a href="#pone-0026005-t002">Table 2</a>). Of note, median times to reinfection, a sensitive measure for the post-treatment suppressive efficacy of the long-half life companion drugs PPQ and LM remained stable throughout the study (<a href="#pone-0026005-t002">Table 2</a>).</p> <a class="link-target" id="pone-0026005-g002" name="pone-0026005-g002"></a><div class="figure" data-doi="10.1371/journal.pone.0026005.g002"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&id=10.1371/journal.pone.0026005.g002" data-doi="10.1371/journal.pone.0026005" data-uri="10.1371/journal.pone.0026005.g002"><img src="article/figure/image?size=inline&id=10.1371/journal.pone.0026005.g002" alt="thumbnail" class="thumbnail" loading="lazy"></a><div class="expand"></div></div><div class="figure-inline-download"> Download: <ul><li><a href="article/figure/powerpoint?id=10.1371/journal.pone.0026005.g002"><div class="definition-label">PPT</div><div class="definition-description">PowerPoint slide</div></a></li><li><a href="article/figure/image?download&size=large&id=10.1371/journal.pone.0026005.g002"><div class="definition-label">PNG</div><div class="definition-description">larger image</div></a></li><li><a href="article/figure/image?download&size=original&id=10.1371/journal.pone.0026005.g002"><div class="definition-label">TIFF</div><div class="definition-description">original image</div></a></li></ul></div><div class="figcaption"><span>Figure 2. </span> Scatter plot of day 1 parasite reduction ratios (PRR<sub>D1</sub>) in children with uncomplicated <em>P. falciparum</em> malaria by treatment group over time.</div><p class="caption_target"><a id="article1.body1.sec3.sec2.fig1.caption1.p1" name="article1.body1.sec3.sec2.fig1.caption1.p1" class="link-target"></a><p>Solid and hollow circles represent PRR<sub>D1</sub>s from patients treated with DHA-PPQ and AM-LM, respectively. Solid and dashed lines indicate linear regression lines for the two treatment groups, respectively. In 2007–2008 an expansion of parasitemia after start of treatment was observed in some patients treated with AM-LM.</p> </p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0026005.g002"> https://doi.org/10.1371/journal.pone.0026005.g002</a></p></div></div> <div id="section3" class="section toc-section"><a id="s3c" name="s3c" class="link-target" title="Pharmacokinetic parameters of drug exposure"></a> <h3>Pharmacokinetic parameters of drug exposure</h3> <a id="article1.body1.sec3.sec3.p1" name="article1.body1.sec3.sec3.p1" class="link-target"></a><p>A total of 105 and 101 serum samples obtained on day 7 from patients who received either DHA-PPQ or AM-LM were analyzed for piperaquine and lumefantrine, respectively. Day 7 serum concentrations did not differ between the two study periods (all p values>0.3) (<a href="#pone.0026005.s004">Table S1</a>). Since samples were unavailable for directly determining plasma concentrations of artemisinin derivatives, we compared body weight-adjusted doses of DHA and AM as proxy of plasma drug exposure, respectively. Although median doses of both DHA and AM were slightly lower in 2007–2008 compared to 2005–2006 (<a href="#pone.0026005.s004">Table S1</a>), day 1 parasite reduction ratios dropped independently in children above or below average body weight-adjusted doses (<a href="#pone.0026005.s004">Table S1</a>).</p> </div> <div id="section4" class="section toc-section"><a id="s3d" name="s3d" class="link-target" title="Clinical, epidemiological and serological parameters of immunity"></a> <h3>Clinical, epidemiological and serological parameters of immunity</h3> <a id="article1.body1.sec3.sec4.p1" name="article1.body1.sec3.sec4.p1" class="link-target"></a><p>We observed a reduced tolerance to any parasitemia but in particular, high-density parasitemia in children enrolled in the second compared with the first study period (<a href="#pone-0026005-g003">Fig. 3</a>; OR for body temperature >37.5°C, 2.8, 1.9–4.1; <em>P</em><0.001). This apparent loss in population-level clinical immunity could not be explained by lower numbers of previous recorded exposure in study participants (2.2 <em>vs.</em> 1.9 previous malaria episodes in 2005–2006 and 2007–2008, respectively; <em>P</em> = 0.4) or serological indices of exposure (median OD of anti-schizont antibodies of 0.71 <em>vs.</em> 0.62 in 2005–2006 <em>vs.</em> 2007–2008, respectively; <em>P</em> = 0.3) (<a href="#pone-0026005-t001">Table 1</a> and <a href="#pone.0026005.s001">Fig. S1</a>).</p> <a class="link-target" id="pone-0026005-g003" name="pone-0026005-g003"></a><div class="figure" data-doi="10.1371/journal.pone.0026005.g003"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&id=10.1371/journal.pone.0026005.g003" data-doi="10.1371/journal.pone.0026005" data-uri="10.1371/journal.pone.0026005.g003"><img src="article/figure/image?size=inline&id=10.1371/journal.pone.0026005.g003" alt="thumbnail" class="thumbnail" loading="lazy"></a><div class="expand"></div></div><div class="figure-inline-download"> Download: <ul><li><a href="article/figure/powerpoint?id=10.1371/journal.pone.0026005.g003"><div class="definition-label">PPT</div><div class="definition-description">PowerPoint slide</div></a></li><li><a href="article/figure/image?download&size=large&id=10.1371/journal.pone.0026005.g003"><div class="definition-label">PNG</div><div class="definition-description">larger image</div></a></li><li><a href="article/figure/image?download&size=original&id=10.1371/journal.pone.0026005.g003"><div class="definition-label">TIFF</div><div class="definition-description">original image</div></a></li></ul></div><div class="figcaption"><span>Figure 3. </span> Locally weighted regression (LOWESS) lines of baseline body temperature by baseline asexual parasite density.</div><p class="caption_target"><a id="article1.body1.sec3.sec4.fig1.caption1.p1" name="article1.body1.sec3.sec4.fig1.caption1.p1" class="link-target"></a><p>The dashed line for patients enrolled in 2007–2008 indicates a substantial reduction in clinical tolerance of patients to high parasitemias as compared to patients enrolled in 2005–2006 (solid line).</p> </p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0026005.g003"> https://doi.org/10.1371/journal.pone.0026005.g003</a></p></div></div> <div id="section5" class="section toc-section"><a id="s3e" name="s3e" class="link-target" title="Multivariable analysis of parasite elimination rate"></a> <h3>Multivariable analysis of parasite elimination rate</h3> <a id="article1.body1.sec3.sec5.p1" name="article1.body1.sec3.sec5.p1" class="link-target"></a><p>In a multivariable logistic regression model only enrollment in 2007–2008, baseline parasitemia, body temperature and treatment group independently predicted PPR<sub>D1</sub> (OR>1.9 and <em>P</em><0.001) (<a href="#pone-0026005-t003">Table 3</a>). Anti-schizont antibody levels did not predict PPR<sub>D1</sub> in a univariable analysis (<a href="#pone-0026005-t003">Table 3</a>).</p> <a class="link-target" id="pone-0026005-t003" name="pone-0026005-t003"></a><div class="figure" data-doi="10.1371/journal.pone.0026005.t003"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&id=10.1371/journal.pone.0026005.t003" data-doi="10.1371/journal.pone.0026005" data-uri="10.1371/journal.pone.0026005.t003"><img src="article/figure/image?size=inline&id=10.1371/journal.pone.0026005.t003" alt="thumbnail" class="thumbnail" loading="lazy"></a><div class="expand"></div></div><div class="figure-inline-download"> Download: <ul><li><a href="article/figure/powerpoint?id=10.1371/journal.pone.0026005.t003"><div class="definition-label">PPT</div><div class="definition-description">PowerPoint slide</div></a></li><li><a href="article/figure/image?download&size=large&id=10.1371/journal.pone.0026005.t003"><div class="definition-label">PNG</div><div class="definition-description">larger image</div></a></li><li><a href="article/figure/image?download&size=original&id=10.1371/journal.pone.0026005.t003"><div class="definition-label">TIFF</div><div class="definition-description">original image</div></a></li></ul></div><div class="figcaption"><span>Table 3. </span> Univariable and multivariable analysis of the risk of residual parasitemia on day 1 after initiation of treatment.</div><p class="caption_target"></p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0026005.t003"> https://doi.org/10.1371/journal.pone.0026005.t003</a></p></div><a id="article1.body1.sec3.sec5.p2" name="article1.body1.sec3.sec5.p2" class="link-target"></a><p>To further dissect potential associations of covariates with the decline through time of parasite elimination rate, risk of parasitemia on day 1 (PPR<sub>D1</sub>) was analyzed for time differences with baseline parasitemia as a continuous covariate. When this was done, the differences between time periods remained, particularly for those patients with low baseline parasitemia (<a href="#pone.0026005.s002">Fig. S2A</a>) (interaction term <em>P</em> = 0.06). Thus the least parasitized children experienced the greatest decrease in efficacy through time. The risk of parasitemia on day 1 was also significantly higher in children enrolled in 2007–2008 after adjusting for patient age (<a href="#pone.0026005.s002">Fig. S2B</a>) and body weight-adjusted DHA dose (<a href="#pone.0026005.s002">Fig. S2C</a>) (<em>P</em><sub>period</sub><0.005 for all comparisons). Similar results were obtained for AM-LM (<a href="#pone.0026005.s002">Fig. S2D–F</a>).</p> </div> <div id="section6" class="section toc-section"><a id="s3f" name="s3f" class="link-target" title="In vitro drug responses and genetic markers"></a> <h3><em>In vitro</em> drug responses and genetic markers</h3> <a id="article1.body1.sec3.sec6.p1" name="article1.body1.sec3.sec6.p1" class="link-target"></a><p>Baseline IC<sub>50</sub> responses for DHA (n = 59), PPQ (n = 53) and LM (n = 60) were not associated with PPR<sub>D1</sub> (data not shown; <em>P</em>>0.2 by logistic regression). Paradoxically, median DHA IC<sub>50</sub> values dropped from 2.2 nM in 2005–2006 (n = 39) to 0.8 nM in 2007–2008 (n = 20) (<em>P</em><0.001; <a href="#pone.0026005.s003">Fig. S3A</a>). <em>In vitro</em> activities of PPQ or LM did not change over the same period of time (<a href="#pone.0026005.s003">Fig. S3B</a>, C; <em>P</em>>0.3).</p> <a id="article1.body1.sec3.sec6.p2" name="article1.body1.sec3.sec6.p2" class="link-target"></a><p>Only 2/84 patients at baseline and 1/52 patients at recurrence (all in second period) were found to harbor infections with >1 copy of <em>MDR1</em> per parasite genome (<a href="#pone-0026005-t001">Table 1</a>).</p> </div> </div> <div xmlns:plos="http://plos.org" id="section4" class="section toc-section"><a id="s4" name="s4" data-toc="s4" class="link-target" title="Discussion"></a><h2>Discussion</h2><a id="article1.body1.sec4.p1" name="article1.body1.sec4.p1" class="link-target"></a><p>Here we report a significant decline of early response rates of <em>P. falciparum</em> infections to treatment with ACTs after three years of their use in a randomized controlled clinical trial and less than two years after the introduction of AM-LM as first-line treatment in the Coast Province of Kenya. The parasite prevalence rate on day 1, which is primarily determined by the fast acting artemisinin component of ACTs <a href="#pone.0026005-White1" class="ref-tip">[23]</a>, increased from 55% to 87% in patients receiving DHA-PPQ. In parallel, risk of recrudescences until day 84 doubled, although potential misclassification of re- infections detected after day 42 as recrudescent infections due to genotyping artifacts <a href="#pone.0026005-Borrmann1" class="ref-tip">[22]</a>, <a href="#pone.0026005-Juliano1" class="ref-tip">[24]</a> calls for a careful interpretation of these data. Similar results were obtained in patients treated with AM-LM. This is the first report of a decline in the responsiveness to ACTs from a malaria-endemic area outside of Southeast Asia. It is important to note that the magnitude of the decreased response rates observed here is much smaller than the substantially delayed clearance of <em>P. falciparum</em> infection reported from Western Cambodia (times to parasite clearance of 48 hours <em>vs.</em> 84 hours, respectively) <a href="#pone.0026005-Dondorp1" class="ref-tip">[6]</a>, and does not meet current WHO working criteria for emerging <em>in vivo</em> artemisinin resistance <a href="#pone.0026005-WHO2" class="ref-tip">[25]</a>. In particular, all infections in our study treated with full and correctly dosed ACT regimens cleared before day 3. However, the observed increase in the presence of parasites after one day of treatment is reminiscent of incremental changes reported from the Thai-Burmese border in 2001 after 6 years of regulated use of artemisinin combinations in that region <a href="#pone.0026005-Carrara1" class="ref-tip">[26]</a>.</p> <a id="article1.body1.sec4.p2" name="article1.body1.sec4.p2" class="link-target"></a><p>What factors could plausibly have caused the observed drop in early treatment responses measured at peak drug exposure? On average children enrolled in 2007–2008 were 6 months older (<em>P</em><0.05), had higher body temperatures (0.6°C; <em>P</em><0.001), and had 1.3-fold higher baseline parasite densities (<em>P</em><0.05). These differences are most likely to be a consequence of decreased transmission in the study area that occurred mainly before 2005 <a href="#pone.0026005-OMeara1" class="ref-tip">[12]</a>, <a href="#pone.0026005-OMeara2" class="ref-tip">[27]</a>. The latter two parameters, which indicate substantially less clinical immunity in children who grew up after the sharp drop in malaria transmission, were independent strong predictors of the risk of residual parasitemia on day 1 (PPR<sub>D1</sub>) (<a href="#pone-0026005-t003">Table 3</a> and <a href="#pone.0026005.s002">Fig. S2A, D</a>) thus raising the possibility that the decline through time in parasite clearance rates was directly due to a loss of immunity rather than to a change in the level of sensitivity to drugs in the parasite population. However, levels of antibodies against crude blood stage extract did not predict parasite clearance rates and remained stable through time, possibly indicating that these antibodies are insensitive for detecting significant changes in parasite growth-limiting immunity. Moreover, parasite density at the time of enrollment, which is likely to be a good indicator of immunity, did not explain the differences between the time periods in PPR<sub>D1</sub>. Both patient age as a demographic correlate of progressively acquired immunity and specific antibody responses have shown consistent associations with risk of recrudescent primary infections <a href="#pone.0026005-Borrmann1" class="ref-tip">[22]</a>, <a href="#pone.0026005-Borrmann2" class="ref-tip">[28]</a>–<a href="#pone.0026005-Cravo1" class="ref-tip">[32]</a>. The contribution, if any, of acquired antiparasitic immune responses to parasite clearance during peak drug exposure, as observed in this study, is less evident, however <a href="#pone.0026005-Dondorp1" class="ref-tip">[6]</a>, <a href="#pone.0026005-Borrmann2" class="ref-tip">[28]</a>: associations between patient age and early response parameters have been reported for weak or failing drugs <a href="#pone.0026005-Borrmann2" class="ref-tip">[28]</a>, but not, including in this study, for highly active artemisinin drugs <a href="#pone.0026005-Dondorp1" class="ref-tip">[6]</a>. More studies of the relative contributions of immunity, parasite resistance and their interactions to the immediate efficacy of drugs are required.</p> <a id="article1.body1.sec4.p3" name="article1.body1.sec4.p3" class="link-target"></a><p>Is it possible to quantify the extent, if any, to which changes in parasite sensitivity to the drugs could have contributed to the observed progressive reduction in responsiveness to treatment (<a href="#pone-0026005-g002">Fig. 2</a>)? We failed to find <em>in vitro</em> evidence of reduced artemisinin sensitivity in isolates obtained from patients with reduced <em>in vivo</em> response rates that could have suggested a gradual selection of ‘less-sensitive’ parasites. One explanation is that either unstable or <em>in vivo</em>-confined phenotypes may have escaped detection when measuring <em>in vitro</em> growth response rates in culture-adapted isolates. Alternatively, our <em>in vitro</em> test which covers >1 intraerythrocytic replication cycle may have been insensitive to changes in stage-specific artemisinin activity causing prolonged circulation of young ring-form parasites <a href="#pone.0026005-Anderson1" class="ref-tip">[33]</a>, <a href="#pone.0026005-Anderson2" class="ref-tip">[34]</a>. Sustained parasite sensitivity to PPQ and LM (using assays previously shown to detect variation in sensitivity) <a href="#pone.0026005-Mwai1" class="ref-tip">[35]</a>–<a href="#pone.0026005-Wong1" class="ref-tip">[37]</a> suggests that changes of treatment response rates were not due to parasite resistance to PPQ or LM and may help to explain the relatively small increase in parasite clearance times (46 hours in 2007–2008 up from 38 hours in 2005–2006). This conclusion is further supported by initial studies on piperaquine, which on its own can clear infections between 34 and 72 hours and by a recent meta-analysis showing accelerated clearance after treatment with ACTs containing novel drugs compared to compromised partner drugs such as chloroquine <a href="#pone.0026005-Chen1" class="ref-tip">[38]</a>, <a href="#pone.0026005-Stepniewska1" class="ref-tip">[39]</a>. Nevertheless, the confounding and interaction between immunity and potential change in parasite sensitivity in this study cautions against firm conclusions at this stage. We also cannot rule out the possibility that residual concentrations of former first-line drugs chloroquine or sulfadoxine-pyrimethamine contributed to faster parasite clearance during the first period of the study, that is, before the implementation of AM-LM as first-line treatment in 2006.</p> <a id="article1.body1.sec4.p4" name="article1.body1.sec4.p4" class="link-target"></a><p>The observation of declining parasitological response to ACTs in the context of slowly declining malaria transmission intensity in Kilifi and minimal access to monotherapy raises a number of issues. First, immunity appears to play a complex role in parasite clearance during treatment. Second, it seems unlikely that parasites with reduced sensitivity to ACTs have spread from Southeast Asia to East Africa <em>en masse</em> to cause the apparently high prevalence of reduced sensitivity observed here. On the other hand, if tolerance is induced, rather than genetically encoded, for example through epigenetic mechanisms, its rise could be very rapid. Currently, we lack efficient molecular tools for mapping the spread of parasites with altered responsiveness and we do not know whether the observed small changes in responsiveness to treatment, which are reminiscent of long term observations from the Thai-Myanmar border <a href="#pone.0026005-Carrara1" class="ref-tip">[26]</a> are precursors of worse-to-come artemisinin-specific “resistance” as reported from western Thailand <a href="#pone.0026005-Dondorp1" class="ref-tip">[6]</a>. At present, overall clinical response to ACTs remains adequate in Kenya, though decelerated parasite clearance <em>per se</em>, whether due to declining clinical immunity or changes in parasite sensitivity, could potentially impact on the clinical benefit of artemisinins in the treatment of malaria <a href="#pone.0026005-Dondorp3" class="ref-tip">[40]</a>. The observation of reducing response rates to ACTs on the Kenyan coast indicates an urgent need for surveillance of antimalarial drug efficacy in sentinel sites across Africa.</p> </div> <div xmlns:plos="http://plos.org" id="section5" class="section toc-section"><a id="s5" name="s5" data-toc="s5" class="link-target" title="Supporting Information"></a><h2>Supporting Information</h2><div class="figshare_widget" doi="10.1371/journal.pone.0026005"></div><div class="supplementary-material"><a name="pone.0026005.s001" id="pone.0026005.s001" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&id=10.1371/journal.pone.0026005.s001">Figure S1. </a></h3><a id="article1.body1.sec5.supplementary-material1.caption1.p1" name="article1.body1.sec5.supplementary-material1.caption1.p1" class="link-target"></a><p class="preSiDOI">Dot plots of anti-<em>P. falciparum</em> schizont antibody responses (optical density) measured at baseline in children enrolled in 2005–2006 <em>vs.</em> 2007–2008. Solid lines represent medians and dashed lines indicate binomial 95% confidence intervals.</p> <p class="siDoi"><a href="https://doi.org/10.1371/journal.pone.0026005.s001">https://doi.org/10.1371/journal.pone.0026005.s001</a></p><a id="article1.body1.sec5.supplementary-material1.caption1.p2" name="article1.body1.sec5.supplementary-material1.caption1.p2" class="link-target"></a><p class="postSiDOI">(EPS)</p> </div><div class="supplementary-material"><a name="pone.0026005.s002" id="pone.0026005.s002" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&id=10.1371/journal.pone.0026005.s002">Figure S2. </a></h3><a id="article1.body1.sec5.supplementary-material2.caption1.p1" name="article1.body1.sec5.supplementary-material2.caption1.p1" class="link-target"></a><p class="preSiDOI">Fitted curves of the risk of residual parasitemia on day 1 in patients treated with DHA-PPQ (A–C) and AM-LM (D–F). The risk of day 1 parasitemia was fitted using logistic regression for baseline parasite density (A, D), patient age (B, E), and body-weight adjusted doses of DHA (C) and AM (F). Black lines represent predicted risk in patients enrolled in 2005–2006 and gray lines represent predicted risk in patients enrolled in 2007–2008.</p> <p class="siDoi"><a href="https://doi.org/10.1371/journal.pone.0026005.s002">https://doi.org/10.1371/journal.pone.0026005.s002</a></p><a id="article1.body1.sec5.supplementary-material2.caption1.p2" name="article1.body1.sec5.supplementary-material2.caption1.p2" class="link-target"></a><p class="postSiDOI">(EPS)</p> </div><div class="supplementary-material"><a name="pone.0026005.s003" id="pone.0026005.s003" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&id=10.1371/journal.pone.0026005.s003">Figure S3. </a></h3><a id="article1.body1.sec5.supplementary-material3.caption1.p1" name="article1.body1.sec5.supplementary-material3.caption1.p1" class="link-target"></a><p class="preSiDOI">Dot plots of half-maximal inhibitory concentrations (IC<sub>50</sub>) of culture-adapted <em>P. falciparum</em> isolates collected from patients in 2005–2006 and 2007–2008. IC<sub>50</sub> responses were determined for dihydroartemisinin (DHA) (<a href="#pone.0026005.s003">Fig. S3A</a>), piperaquine (PPQ) (<a href="#pone.0026005.s003">Fig. S3B</a>) and lumefantrine (LM) (<a href="#pone.0026005.s003">Fig. S3C</a>).</p> <p class="siDoi"><a href="https://doi.org/10.1371/journal.pone.0026005.s003">https://doi.org/10.1371/journal.pone.0026005.s003</a></p><a id="article1.body1.sec5.supplementary-material3.caption1.p2" name="article1.body1.sec5.supplementary-material3.caption1.p2" class="link-target"></a><p class="postSiDOI">(EPS)</p> </div><div class="supplementary-material"><a name="pone.0026005.s004" id="pone.0026005.s004" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&id=10.1371/journal.pone.0026005.s004">Table S1. </a></h3><a id="article1.body1.sec5.supplementary-material4.caption1.p1" name="article1.body1.sec5.supplementary-material4.caption1.p1" class="link-target"></a><p class="preSiDOI">Relationship between pharmacokinetic and pharmacodynamic parameters over time.</p> <p class="siDoi"><a href="https://doi.org/10.1371/journal.pone.0026005.s004">https://doi.org/10.1371/journal.pone.0026005.s004</a></p><a id="article1.body1.sec5.supplementary-material4.caption1.p2" name="article1.body1.sec5.supplementary-material4.caption1.p2" class="link-target"></a><p class="postSiDOI">(DOC)</p> </div><div class="supplementary-material"><a name="pone.0026005.s005" id="pone.0026005.s005" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&id=10.1371/journal.pone.0026005.s005">Protocol S1. </a></h3><a id="article1.body1.sec5.supplementary-material5.caption1.p1" name="article1.body1.sec5.supplementary-material5.caption1.p1" class="link-target"></a><p class="preSiDOI">Trial Protocol.</p> <p class="siDoi"><a href="https://doi.org/10.1371/journal.pone.0026005.s005">https://doi.org/10.1371/journal.pone.0026005.s005</a></p><a id="article1.body1.sec5.supplementary-material5.caption1.p2" name="article1.body1.sec5.supplementary-material5.caption1.p2" class="link-target"></a><p class="postSiDOI">(DOC)</p> </div><div class="supplementary-material"><a name="pone.0026005.s006" id="pone.0026005.s006" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&id=10.1371/journal.pone.0026005.s006">Checklist S1. </a></h3><a id="article1.body1.sec5.supplementary-material6.caption1.p1" name="article1.body1.sec5.supplementary-material6.caption1.p1" class="link-target"></a><p class="preSiDOI">CONSORT Checklist.</p> <p class="siDoi"><a href="https://doi.org/10.1371/journal.pone.0026005.s006">https://doi.org/10.1371/journal.pone.0026005.s006</a></p><a id="article1.body1.sec5.supplementary-material6.caption1.p2" name="article1.body1.sec5.supplementary-material6.caption1.p2" class="link-target"></a><p class="postSiDOI">(DOC)</p> </div></div> <div xmlns:plos="http://plos.org" class="section toc-section"><a id="ack" name="ack" data-toc="ack" title="Acknowledgments" class="link-target"></a><h2>Acknowledgments</h2> <a id="article1.back1.ack1.p1" name="article1.back1.ack1.p1" class="link-target"></a><p>We are indebted to the participating children and their parents. We would like to acknowledge the continued support by our colleagues at the Kenya Medical Research Institute/Wellcome Trust Research Programme in Kilifi for supporting this study, in particularly, the teams at the Clinical Trial Facility (Jacinta Mutegi, Chemtai Kipkeu, Roma Chilengi and Trudie Lang), the Pharmacology Laboratory (Simon Ndirangu), the Pharmacy (Alex Muturi), the Clinical Trials Laboratory (Fixtan Njuga, Ken Awuondo, Gabriel Mwambingu and James Njogu), the Immunology Laboratory (Barnes Kitsao and Martin Mwakala) and the Social Science Group (Dorcas Kamuya, Vicki Marsh and Sassy Molyneux). Special thanks go to the passionate study nurses Ann Kithinji, Joy Lewa, and Crispinah Kaulu. We thank Nimmo Gichero and Linda Murungi for measurement of antibody responses. We would also like to thank Umberto D'Alessandro and Chantal van Overmeir (Antwerp Institute of Tropical Medicine) for sharing genotyping data and Ingrid Felger (Swiss Tropical Institute) for critical help in establishing a capillary electrophoresis-based genotyping protocol. In addition we wish to acknowledge the contributions by Marco Corsi and Antonio Longo (SigmaTau) for provision of study medication and drug quality testing; Marc Cousin, Gilbert Lefèvre and Nathan Mulure (Novartis) also for provision of study medication and stability testing; Jo Hudson, Deirdré Marais and Ambrose Talisuna (MDS) for monitoring and encouragement; David Ubben (MMV) for coordination and Pascal Ringwald (WHO) for discussions.</p> </div><div xmlns:plos="http://plos.org" class="contributions toc-section"><a id="authcontrib" name="authcontrib" data-toc="authcontrib" title="Author Contributions"></a><h2>Author Contributions</h2><p>Conceived and designed the experiments: SB AN M. Mackinnon KM. Performed the experiments: SB PS AA LM MB SM BT BL HF BS JP JP WH AR M. Mosobo. Analyzed the data: SB PS EJ GF NL AN FO NP KM M. Mackinnon. Wrote the paper: SB M. Mackinnon KM.</p></div><div xmlns:plos="http://plos.org" class="toc-section"><a id="references" name="references" class="link-target" data-toc="references" title="References"></a><h2>References</h2><ol class="references"><li id="ref1"><span class="order">1. </span><a name="pone.0026005-Trape1" id="pone.0026005-Trape1" class="link-target"></a>Trape JF, Pison G, Preziosi MP, Enel C, Desgrees du Lou A, et al. (1998) Impact of chloroquine resistance on malaria mortality. C R Acad Sci III 321: 689–697. <ul class="reflinks"><li><a href="#" data-author="Trape" data-cit="TrapeJFPisonGPreziosiMPEnelCDesgrees%20du%20LouA1998Impact%20of%20chloroquine%20resistance%20on%20malaria%20mortality.C%20R%20Acad%20Sci%20III321689697" data-title="Impact%20of%20chloroquine%20resistance%20on%20malaria%20mortality." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Impact+of+chloroquine+resistance+on+malaria+mortality.+Trape+1998" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref2"><span class="order">2. </span><a name="pone.0026005-Baird1" id="pone.0026005-Baird1" class="link-target"></a>Baird JK (2005) Effectiveness of antimalarial drugs. N Engl J Med 352: 1565–1577. <ul class="reflinks"><li><a href="#" data-author="Baird" data-cit="BairdJK2005Effectiveness%20of%20antimalarial%20drugs.N%20Engl%20J%20Med35215651577" data-title="Effectiveness%20of%20antimalarial%20drugs." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Effectiveness+of+antimalarial+drugs.+Baird+2005" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref3"><span class="order">3. </span><a name="pone.0026005-Korenromp1" id="pone.0026005-Korenromp1" class="link-target"></a>Korenromp EL, Williams BG, Gouws E, Dye C, Snow RW (2003) Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis 3: 349–358. <ul class="reflinks"><li><a href="#" data-author="Korenromp" data-cit="KorenrompELWilliamsBGGouwsEDyeCSnowRW2003Measurement%20of%20trends%20in%20childhood%20malaria%20mortality%20in%20Africa%3A%20an%20assessment%20of%20progress%20toward%20targets%20based%20on%20verbal%20autopsy.Lancet%20Infect%20Dis3349358" data-title="Measurement%20of%20trends%20in%20childhood%20malaria%20mortality%20in%20Africa%3A%20an%20assessment%20of%20progress%20toward%20targets%20based%20on%20verbal%20autopsy." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Measurement+of+trends+in+childhood+malaria+mortality+in+Africa%3A+an+assessment+of+progress+toward+targets+based+on+verbal+autopsy.+Korenromp+2003" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref4"><span class="order">4. </span><a name="pone.0026005-Bhattarai1" id="pone.0026005-Bhattarai1" class="link-target"></a>Bhattarai A, Ali AS, Kachur SP, Martensson A, Abbas AK, et al. (2007) Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med 4: e309. <ul class="reflinks"><li><a href="#" data-author="Bhattarai" data-cit="BhattaraiAAliASKachurSPMartenssonAAbbasAK2007Impact%20of%20artemisinin-based%20combination%20therapy%20and%20insecticide-treated%20nets%20on%20malaria%20burden%20in%20Zanzibar.PLoS%20Med4e309" data-title="Impact%20of%20artemisinin-based%20combination%20therapy%20and%20insecticide-treated%20nets%20on%20malaria%20burden%20in%20Zanzibar." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Impact+of+artemisinin-based+combination+therapy+and+insecticide-treated+nets+on+malaria+burden+in+Zanzibar.+Bhattarai+2007" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref5"><span class="order">5. </span><a name="pone.0026005-Barnes1" id="pone.0026005-Barnes1" class="link-target"></a>Barnes KI, Durrheim DN, Little F, Jackson A, Mehta U, et al. (2005) Effect of Artemether-Lumefantrine Policy and Improved Vector Control on Malaria Burden in KwaZulu-Natal, South Africa. PLoS Med 2: e330. <ul class="reflinks"><li><a href="#" data-author="Barnes" data-cit="BarnesKIDurrheimDNLittleFJacksonAMehtaU2005Effect%20of%20Artemether-Lumefantrine%20Policy%20and%20Improved%20Vector%20Control%20on%20Malaria%20Burden%20in%20KwaZulu-Natal%2C%20South%20Africa.PLoS%20Med2e330" data-title="Effect%20of%20Artemether-Lumefantrine%20Policy%20and%20Improved%20Vector%20Control%20on%20Malaria%20Burden%20in%20KwaZulu-Natal%2C%20South%20Africa." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Effect+of+Artemether-Lumefantrine+Policy+and+Improved+Vector+Control+on+Malaria+Burden+in+KwaZulu-Natal%2C+South+Africa.+Barnes+2005" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref6"><span class="order">6. </span><a name="pone.0026005-Dondorp1" id="pone.0026005-Dondorp1" class="link-target"></a>Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, et al. (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455–467. <ul class="reflinks"><li><a href="#" data-author="Dondorp" data-cit="DondorpAMNostenFYiPDasDPhyoAP2009Artemisinin%20resistance%20in%20Plasmodium%20falciparum%20malaria.N%20Engl%20J%20Med361455467" data-title="Artemisinin%20resistance%20in%20Plasmodium%20falciparum%20malaria." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Artemisinin+resistance+in+Plasmodium+falciparum+malaria.+Dondorp+2009" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref7"><span class="order">7. </span><a name="pone.0026005-Noedl1" id="pone.0026005-Noedl1" class="link-target"></a>Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, et al. (2008) Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359: 2619–2620. <ul class="reflinks"><li><a href="#" data-author="Noedl" data-cit="NoedlHSeYSchaecherKSmithBLSocheatD2008Evidence%20of%20artemisinin-resistant%20malaria%20in%20western%20Cambodia.N%20Engl%20J%20Med35926192620" data-title="Evidence%20of%20artemisinin-resistant%20malaria%20in%20western%20Cambodia." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Evidence+of+artemisinin-resistant+malaria+in+western+Cambodia.+Noedl+2008" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref8"><span class="order">8. </span><a name="pone.0026005-Noedl2" id="pone.0026005-Noedl2" class="link-target"></a>Noedl H, Socheat D, Satimai W (2009) Artemisinin-resistant malaria in Asia. N Engl J Med 361: 540–541. <ul class="reflinks"><li><a href="#" data-author="Noedl" data-cit="NoedlHSocheatDSatimaiW2009Artemisinin-resistant%20malaria%20in%20Asia.N%20Engl%20J%20Med361540541" data-title="Artemisinin-resistant%20malaria%20in%20Asia." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Artemisinin-resistant+malaria+in+Asia.+Noedl+2009" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref9"><span class="order">9. </span><a name="pone.0026005-Dondorp2" id="pone.0026005-Dondorp2" class="link-target"></a>Dondorp AM, Yeung S, White L, Nguon C, Day NP, et al. (2010) Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 8: 272–280. <ul class="reflinks"><li><a href="#" data-author="Dondorp" data-cit="DondorpAMYeungSWhiteLNguonCDayNP2010Artemisinin%20resistance%3A%20current%20status%20and%20scenarios%20for%20containment.Nat%20Rev%20Microbiol8272280" data-title="Artemisinin%20resistance%3A%20current%20status%20and%20scenarios%20for%20containment." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Artemisinin+resistance%3A+current+status+and+scenarios+for+containment.+Dondorp+2010" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref10"><span class="order">10. </span><a name="pone.0026005-Sasi1" id="pone.0026005-Sasi1" class="link-target"></a>Sasi P, Abdulrahaman A, Mwai L, Muriithi S, Straimer J, et al. (2009) In vivo and in vitro efficacy of amodiaquine against Plasmodium falciparum in an area of continued use of 4-aminoquinolines in East Africa. J Infect Dis 199: 1575–1582. <ul class="reflinks"><li><a href="#" data-author="Sasi" data-cit="SasiPAbdulrahamanAMwaiLMuriithiSStraimerJ2009In%20vivo%20and%20in%20vitro%20efficacy%20of%20amodiaquine%20against%20Plasmodium%20falciparum%20in%20an%20area%20of%20continued%20use%20of%204-aminoquinolines%20in%20East%20Africa.J%20Infect%20Dis19915751582" data-title="In%20vivo%20and%20in%20vitro%20efficacy%20of%20amodiaquine%20against%20Plasmodium%20falciparum%20in%20an%20area%20of%20continued%20use%20of%204-aminoquinolines%20in%20East%20Africa." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=In+vivo+and+in+vitro+efficacy+of+amodiaquine+against+Plasmodium+falciparum+in+an+area+of+continued+use+of+4-aminoquinolines+in+East+Africa.+Sasi+2009" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref11"><span class="order">11. </span><a name="pone.0026005-Olotu1" id="pone.0026005-Olotu1" class="link-target"></a>Olotu A, Fegan G, Williams TN, Sasi P, Ogada E, et al. (2010) Defining clinical malaria: the specificity and incidence of endpoints from active and passive surveillance of children in rural Kenya. PLoS ONE 5: e15569. <ul class="reflinks"><li><a href="#" data-author="Olotu" data-cit="OlotuAFeganGWilliamsTNSasiPOgadaE2010Defining%20clinical%20malaria%3A%20the%20specificity%20and%20incidence%20of%20endpoints%20from%20active%20and%20passive%20surveillance%20of%20children%20in%20rural%20Kenya.PLoS%20ONE5e15569" data-title="Defining%20clinical%20malaria%3A%20the%20specificity%20and%20incidence%20of%20endpoints%20from%20active%20and%20passive%20surveillance%20of%20children%20in%20rural%20Kenya." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Defining+clinical+malaria%3A+the+specificity+and+incidence+of+endpoints+from+active+and+passive+surveillance+of+children+in+rural+Kenya.+Olotu+2010" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref12"><span class="order">12. </span><a name="pone.0026005-OMeara1" id="pone.0026005-OMeara1" class="link-target"></a>O'Meara WP, Bejon P, Mwangi TW, Okiro EA, Peshu N, et al. (2008) Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet 372: 1555–1562. <ul class="reflinks"><li><a href="#" data-author="O%27Meara" data-cit="O%27MearaWPBejonPMwangiTWOkiroEAPeshuN2008Effect%20of%20a%20fall%20in%20malaria%20transmission%20on%20morbidity%20and%20mortality%20in%20Kilifi%2C%20Kenya.Lancet37215551562" data-title="Effect%20of%20a%20fall%20in%20malaria%20transmission%20on%20morbidity%20and%20mortality%20in%20Kilifi%2C%20Kenya." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Effect+of+a+fall+in+malaria+transmission+on+morbidity+and+mortality+in+Kilifi%2C+Kenya.+O%27Meara+2008" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref13"><span class="order">13. </span><a name="pone.0026005-WHO1" id="pone.0026005-WHO1" class="link-target"></a>WHO (2008) Methods and techniques for clinical trials on antimalarial drug efficacy. Geneva.. <ul class="find-nolinks"></ul></li><li id="ref14"><span class="order">14. </span><a name="pone.0026005-Bassat1" id="pone.0026005-Bassat1" class="link-target"></a>Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, et al. (2009) Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS ONE 4: e7871. <ul class="reflinks"><li><a href="#" data-author="Bassat" data-cit="BassatQMulengaMTintoHPiolaPBorrmannS2009Dihydroartemisinin-piperaquine%20and%20artemether-lumefantrine%20for%20treating%20uncomplicated%20malaria%20in%20African%20children%3A%20a%20randomised%2C%20non-inferiority%20trial.PLoS%20ONE4e7871" data-title="Dihydroartemisinin-piperaquine%20and%20artemether-lumefantrine%20for%20treating%20uncomplicated%20malaria%20in%20African%20children%3A%20a%20randomised%2C%20non-inferiority%20trial." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Dihydroartemisinin-piperaquine+and+artemether-lumefantrine+for+treating+uncomplicated+malaria+in+African+children%3A+a+randomised%2C+non-inferiority+trial.+Bassat+2009" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref15"><span class="order">15. </span><a name="pone.0026005-Felger1" id="pone.0026005-Felger1" class="link-target"></a>Felger I, Beck HP (2002) Genotyping of Plasmodium falciparum. PCR-RFLP analysis. Methods Mol Med 72: 117–129. <ul class="reflinks"><li><a href="#" data-author="Felger" data-cit="FelgerIBeckHP2002Genotyping%20of%20Plasmodium%20falciparum.%20PCR-RFLP%20analysis.Methods%20Mol%20Med72117129" data-title="Genotyping%20of%20Plasmodium%20falciparum.%20PCR-RFLP%20analysis." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Genotyping+of+Plasmodium+falciparum.+PCR-RFLP+analysis.+Felger+2002" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref16"><span class="order">16. </span><a name="pone.0026005-Falk1" id="pone.0026005-Falk1" class="link-target"></a>Falk N, Maire N, Sama W, Owusu-Agyei S, Smith T, et al. (2006) Comparison of PCR-RFLP and Genescan-based genotyping for analyzing infection dynamics of Plasmodium falciparum. Am J Trop Med Hyg 74: 944–950. <ul class="reflinks"><li><a href="#" data-author="Falk" data-cit="FalkNMaireNSamaWOwusu-AgyeiSSmithT2006Comparison%20of%20PCR-RFLP%20and%20Genescan-based%20genotyping%20for%20analyzing%20infection%20dynamics%20of%20Plasmodium%20falciparum.Am%20J%20Trop%20Med%20Hyg74944950" data-title="Comparison%20of%20PCR-RFLP%20and%20Genescan-based%20genotyping%20for%20analyzing%20infection%20dynamics%20of%20Plasmodium%20falciparum." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Comparison+of+PCR-RFLP+and+Genescan-based+genotyping+for+analyzing+infection+dynamics+of+Plasmodium+falciparum.+Falk+2006" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref17"><span class="order">17. </span><a name="pone.0026005-Price1" id="pone.0026005-Price1" class="link-target"></a>Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, et al. (2004) Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364: 438–447. <ul class="reflinks"><li><a href="#" data-author="Price" data-cit="PriceRNUhlemannACBrockmanAMcGreadyRAshleyE2004Mefloquine%20resistance%20in%20Plasmodium%20falciparum%20and%20increased%20pfmdr1%20gene%20copy%20number.Lancet364438447" data-title="Mefloquine%20resistance%20in%20Plasmodium%20falciparum%20and%20increased%20pfmdr1%20gene%20copy%20number." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Mefloquine+resistance+in+Plasmodium+falciparum+and+increased+pfmdr1+gene+copy+number.+Price+2004" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref18"><span class="order">18. </span><a name="pone.0026005-Annerberg1" id="pone.0026005-Annerberg1" class="link-target"></a>Annerberg A, Singtoroj T, Tipmanee P, White NJ, Day NP, et al. (2005) High throughput assay for the determination of lumefantrine in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 822: 330–333. <ul class="reflinks"><li><a href="#" data-author="Annerberg" data-cit="AnnerbergASingtorojTTipmaneePWhiteNJDayNP2005High%20throughput%20assay%20for%20the%20determination%20of%20lumefantrine%20in%20plasma.J%20Chromatogr%20B%20Analyt%20Technol%20Biomed%20Life%20Sci822330333" data-title="High%20throughput%20assay%20for%20the%20determination%20of%20lumefantrine%20in%20plasma." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=High+throughput+assay+for+the+determination+of+lumefantrine+in+plasma.+Annerberg+2005" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref19"><span class="order">19. </span><a name="pone.0026005-Lindegardh1" id="pone.0026005-Lindegardh1" class="link-target"></a>Lindegardh N, Annerberg A, White NJ, Day NP (2008) Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects. J Chromatogr B Analyt Technol Biomed Life Sci 862: 227–236. <ul class="reflinks"><li><a href="#" data-author="Lindegardh" data-cit="LindegardhNAnnerbergAWhiteNJDayNP2008Development%20and%20validation%20of%20a%20liquid%20chromatographic-tandem%20mass%20spectrometric%20method%20for%20determination%20of%20piperaquine%20in%20plasma%20stable%20isotope%20labeled%20internal%20standard%20does%20not%20always%20compensate%20for%20matrix%20effects.J%20Chromatogr%20B%20Analyt%20Technol%20Biomed%20Life%20Sci862227236" data-title="Development%20and%20validation%20of%20a%20liquid%20chromatographic-tandem%20mass%20spectrometric%20method%20for%20determination%20of%20piperaquine%20in%20plasma%20stable%20isotope%20labeled%20internal%20standard%20does%20not%20always%20compensate%20for%20matrix%20effects." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Development+and+validation+of+a+liquid+chromatographic-tandem+mass+spectrometric+method+for+determination+of+piperaquine+in+plasma+stable+isotope+labeled+internal+standard+does+not+always+compensate+for+matrix+effects.+Lindegardh+2008" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref20"><span class="order">20. </span><a name="pone.0026005-Osier1" id="pone.0026005-Osier1" class="link-target"></a>Osier FH, Fegan G, Polley SD, Murungi L, Verra F, et al. (2008) Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 76: 2240–2248. <ul class="reflinks"><li><a href="#" data-author="Osier" data-cit="OsierFHFeganGPolleySDMurungiLVerraF2008Breadth%20and%20magnitude%20of%20antibody%20responses%20to%20multiple%20Plasmodium%20falciparum%20merozoite%20antigens%20are%20associated%20with%20protection%20from%20clinical%20malaria.Infect%20Immun7622402248" data-title="Breadth%20and%20magnitude%20of%20antibody%20responses%20to%20multiple%20Plasmodium%20falciparum%20merozoite%20antigens%20are%20associated%20with%20protection%20from%20clinical%20malaria." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Breadth+and+magnitude+of+antibody+responses+to+multiple+Plasmodium+falciparum+merozoite+antigens+are+associated+with+protection+from+clinical+malaria.+Osier+2008" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref21"><span class="order">21. </span><a name="pone.0026005-McMorran1" id="pone.0026005-McMorran1" class="link-target"></a>McMorran BJ, Marshall VM, de Graaf C, Drysdale KE, Shabbar M, et al. (2009) Platelets kill intraerythrocytic malarial parasites and mediate survival to infection. Science 323: 797–800. <ul class="reflinks"><li><a href="#" data-author="McMorran" data-cit="McMorranBJMarshallVMde%20GraafCDrysdaleKEShabbarM2009Platelets%20kill%20intraerythrocytic%20malarial%20parasites%20and%20mediate%20survival%20to%20infection.Science323797800" data-title="Platelets%20kill%20intraerythrocytic%20malarial%20parasites%20and%20mediate%20survival%20to%20infection." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Platelets+kill+intraerythrocytic+malarial+parasites+and+mediate+survival+to+infection.+McMorran+2009" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref22"><span class="order">22. </span><a name="pone.0026005-Borrmann1" id="pone.0026005-Borrmann1" class="link-target"></a>Borrmann S, Peto T, Snow RW, Gutteridge W, White NJ (2008) Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria. Plos Med 5: e227. <ul class="reflinks"><li><a href="#" data-author="Borrmann" data-cit="BorrmannSPetoTSnowRWGutteridgeWWhiteNJ2008Revisiting%20the%20design%20of%20phase%20III%20clinical%20trials%20of%20antimalarial%20drugs%20for%20uncomplicated%20Plasmodium%20falciparum%20malaria.Plos%20Med5e227" data-title="Revisiting%20the%20design%20of%20phase%20III%20clinical%20trials%20of%20antimalarial%20drugs%20for%20uncomplicated%20Plasmodium%20falciparum%20malaria." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Revisiting+the+design+of+phase+III+clinical+trials+of+antimalarial+drugs+for+uncomplicated+Plasmodium+falciparum+malaria.+Borrmann+2008" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref23"><span class="order">23. </span><a name="pone.0026005-White1" id="pone.0026005-White1" class="link-target"></a>White NJ (2004) Antimalarial drug resistance. J Clin Invest 113: 1084–1092. <ul class="reflinks"><li><a href="#" data-author="White" data-cit="WhiteNJ2004Antimalarial%20drug%20resistance.J%20Clin%20Invest11310841092" data-title="Antimalarial%20drug%20resistance." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Antimalarial+drug+resistance.+White+2004" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref24"><span class="order">24. </span><a name="pone.0026005-Juliano1" id="pone.0026005-Juliano1" class="link-target"></a>Juliano JJ, Gadalla N, Sutherland CJ, Meshnick SR (2010) The perils of PCR: can we accurately ‘correct’ antimalarial trials? Trends Parasitol 26: 119–124. <ul class="reflinks"><li><a href="#" data-author="Juliano" data-cit="JulianoJJGadallaNSutherlandCJMeshnickSR2010The%20perils%20of%20PCR%3A%20can%20we%20accurately%20%E2%80%98correct%E2%80%99%20antimalarial%20trials%3FTrends%20Parasitol26119124" data-title="The%20perils%20of%20PCR%3A%20can%20we%20accurately%20%E2%80%98correct%E2%80%99%20antimalarial%20trials%3F" target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=The+perils+of+PCR%3A+can+we+accurately+%E2%80%98correct%E2%80%99+antimalarial+trials%3F+Juliano+2010" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref25"><span class="order">25. </span><a name="pone.0026005-WHO2" id="pone.0026005-WHO2" class="link-target"></a>WHO (2010) World Malaria Report 2010. Geneva. <ul class="find-nolinks"></ul></li><li id="ref26"><span class="order">26. </span><a name="pone.0026005-Carrara1" id="pone.0026005-Carrara1" class="link-target"></a>Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, et al. (2009) Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS ONE 4: e4551. <ul class="reflinks"><li><a href="#" data-author="Carrara" data-cit="CarraraVIZwangJAshleyEAPriceRNStepniewskaK2009Changes%20in%20the%20treatment%20responses%20to%20artesunate-mefloquine%20on%20the%20northwestern%20border%20of%20Thailand%20during%2013%20years%20of%20continuous%20deployment.PLoS%20ONE4e4551" data-title="Changes%20in%20the%20treatment%20responses%20to%20artesunate-mefloquine%20on%20the%20northwestern%20border%20of%20Thailand%20during%2013%20years%20of%20continuous%20deployment." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Changes+in+the+treatment+responses+to+artesunate-mefloquine+on+the+northwestern+border+of+Thailand+during+13+years+of+continuous+deployment.+Carrara+2009" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref27"><span class="order">27. </span><a name="pone.0026005-OMeara2" id="pone.0026005-OMeara2" class="link-target"></a>O'Meara WP, Mwangi TW, Williams TN, McKenzie FE, Snow RW, et al. (2008) Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. Am J Trop Med Hyg 79: 185–191. <ul class="reflinks"><li><a href="#" data-author="O%27Meara" data-cit="O%27MearaWPMwangiTWWilliamsTNMcKenzieFESnowRW2008Relationship%20between%20exposure%2C%20clinical%20malaria%2C%20and%20age%20in%20an%20area%20of%20changing%20transmission%20intensity.Am%20J%20Trop%20Med%20Hyg79185191" data-title="Relationship%20between%20exposure%2C%20clinical%20malaria%2C%20and%20age%20in%20an%20area%20of%20changing%20transmission%20intensity." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Relationship+between+exposure%2C+clinical+malaria%2C+and+age+in+an+area+of+changing+transmission+intensity.+O%27Meara+2008" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref28"><span class="order">28. </span><a name="pone.0026005-Borrmann2" id="pone.0026005-Borrmann2" class="link-target"></a>Borrmann S, Matsiegui PB, Missinou MA, Kremsner PG (2008) Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in children. Antimicrob Agents Chemother 52: 1799–1805. <ul class="reflinks"><li><a href="#" data-author="Borrmann" data-cit="BorrmannSMatsieguiPBMissinouMAKremsnerPG2008Effects%20of%20Plasmodium%20falciparum%20parasite%20population%20size%20and%20patient%20age%20on%20early%20and%20late%20parasitological%20outcomes%20of%20antimalarial%20treatment%20in%20children.Antimicrob%20Agents%20Chemother5217991805" data-title="Effects%20of%20Plasmodium%20falciparum%20parasite%20population%20size%20and%20patient%20age%20on%20early%20and%20late%20parasitological%20outcomes%20of%20antimalarial%20treatment%20in%20children." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Effects+of+Plasmodium+falciparum+parasite+population+size+and+patient+age+on+early+and+late+parasitological+outcomes+of+antimalarial+treatment+in+children.+Borrmann+2008" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref29"><span class="order">29. </span><a name="pone.0026005-Djimde1" id="pone.0026005-Djimde1" class="link-target"></a>Djimde AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, et al. (2003) Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 69: 558–563. <ul class="reflinks"><li><a href="#" data-author="Djimde" data-cit="DjimdeAADoumboOKTraoreOGuindoABKayentaoK2003Clearance%20of%20drug-resistant%20parasites%20as%20a%20model%20for%20protective%20immunity%20in%20Plasmodium%20falciparum%20malaria.Am%20J%20Trop%20Med%20Hyg69558563" data-title="Clearance%20of%20drug-resistant%20parasites%20as%20a%20model%20for%20protective%20immunity%20in%20Plasmodium%20falciparum%20malaria." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Clearance+of+drug-resistant+parasites+as+a+model+for+protective+immunity+in+Plasmodium+falciparum+malaria.+Djimde+2003" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref30"><span class="order">30. </span><a name="pone.0026005-MawiliMboumba1" id="pone.0026005-MawiliMboumba1" class="link-target"></a>Mawili-Mboumba DP, Borrmann S, Cavanagh DR, McBride JS, Matsiegui PB, et al. (2003) Antibody responses to Plasmodium falciparum merozoite surface protein-1 and efficacy of amodiaquine in Gabonese children with P. falciparum malaria. J Infect Dis 187: 1137–1141. <ul class="reflinks"><li><a href="#" data-author="Mawili-Mboumba" data-cit="Mawili-MboumbaDPBorrmannSCavanaghDRMcBrideJSMatsieguiPB2003Antibody%20responses%20to%20Plasmodium%20falciparum%20merozoite%20surface%20protein-1%20and%20efficacy%20of%20amodiaquine%20in%20Gabonese%20children%20with%20P.%20falciparum%20malaria.J%20Infect%20Dis18711371141" data-title="Antibody%20responses%20to%20Plasmodium%20falciparum%20merozoite%20surface%20protein-1%20and%20efficacy%20of%20amodiaquine%20in%20Gabonese%20children%20with%20P.%20falciparum%20malaria." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Antibody+responses+to+Plasmodium+falciparum+merozoite+surface+protein-1+and+efficacy+of+amodiaquine+in+Gabonese+children+with+P.+falciparum+malaria.+Mawili-Mboumba+2003" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref31"><span class="order">31. </span><a name="pone.0026005-Mayxay1" id="pone.0026005-Mayxay1" class="link-target"></a>Mayxay M, Chotivanich K, Pukrittayakamee S, Newton P, Looareesuwan S, et al. (2001) Contribution of humoral immunity to the therapeutic response in falciparum malaria. Am J Trop Med Hyg 65: 918–923. <ul class="reflinks"><li><a href="#" data-author="Mayxay" data-cit="MayxayMChotivanichKPukrittayakameeSNewtonPLooareesuwanS2001Contribution%20of%20humoral%20immunity%20to%20the%20therapeutic%20response%20in%20falciparum%20malaria.Am%20J%20Trop%20Med%20Hyg65918923" data-title="Contribution%20of%20humoral%20immunity%20to%20the%20therapeutic%20response%20in%20falciparum%20malaria." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Contribution+of+humoral+immunity+to+the+therapeutic+response+in+falciparum+malaria.+Mayxay+2001" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref32"><span class="order">32. </span><a name="pone.0026005-Cravo1" id="pone.0026005-Cravo1" class="link-target"></a>Cravo P, Culleton R, Hunt P, Walliker D, Mackinnon MJ (2001) Antimalarial drugs clear resistant parasites from partially immune hosts. Antimicrob Agents Chemother 45: 2897–2901. <ul class="reflinks"><li><a href="#" data-author="Cravo" data-cit="CravoPCulletonRHuntPWallikerDMackinnonMJ2001Antimalarial%20drugs%20clear%20resistant%20parasites%20from%20partially%20immune%20hosts.Antimicrob%20Agents%20Chemother4528972901" data-title="Antimalarial%20drugs%20clear%20resistant%20parasites%20from%20partially%20immune%20hosts." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Antimalarial+drugs+clear+resistant+parasites+from+partially+immune+hosts.+Cravo+2001" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref33"><span class="order">33. </span><a name="pone.0026005-Anderson1" id="pone.0026005-Anderson1" class="link-target"></a>Anderson TJ, Nair S, Nkhoma S, Williams JT, Imwong M, et al. (2010) High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J Infect Dis 201: 1326–1330. <ul class="reflinks"><li><a href="#" data-author="Anderson" data-cit="AndersonTJNairSNkhomaSWilliamsJTImwongM2010High%20heritability%20of%20malaria%20parasite%20clearance%20rate%20indicates%20a%20genetic%20basis%20for%20artemisinin%20resistance%20in%20western%20Cambodia.J%20Infect%20Dis20113261330" data-title="High%20heritability%20of%20malaria%20parasite%20clearance%20rate%20indicates%20a%20genetic%20basis%20for%20artemisinin%20resistance%20in%20western%20Cambodia." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=High+heritability+of+malaria+parasite+clearance+rate+indicates+a+genetic+basis+for+artemisinin+resistance+in+western+Cambodia.+Anderson+2010" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref34"><span class="order">34. </span><a name="pone.0026005-Anderson2" id="pone.0026005-Anderson2" class="link-target"></a>Anderson TJ, Williams JT, Nair S, Sudimack D, Barends M, et al. (2010) Inferred relatedness and heritability in malaria parasites. Proc Biol Sci. (Epub ahead of print). <ul class="reflinks"><li><a href="#" data-author="Anderson" data-cit="AndersonTJWilliamsJTNairSSudimackDBarendsM2010Inferred%20relatedness%20and%20heritability%20in%20malaria%20parasites.Proc%20Biol%20Sci%28Epub%20ahead%20of%20print%29" data-title="Inferred%20relatedness%20and%20heritability%20in%20malaria%20parasites." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Inferred+relatedness+and+heritability+in+malaria+parasites.+Anderson+2010" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref35"><span class="order">35. </span><a name="pone.0026005-Mwai1" id="pone.0026005-Mwai1" class="link-target"></a>Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, et al. (2009) In vitro activity of piperaquine, lumefantrine and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in Pfcrt and Pfmdr1. Antimicrob Agents Chemother 53: 5069–5073. <ul class="reflinks"><li><a href="#" data-author="Mwai" data-cit="MwaiLKiaraSMAbdirahmanAPoleLRippertA2009In%20vitro%20activity%20of%20piperaquine%2C%20lumefantrine%20and%20dihydroartemisinin%20in%20Kenyan%20Plasmodium%20falciparum%20isolates%20and%20polymorphisms%20in%20Pfcrt%20and%20Pfmdr1.Antimicrob%20Agents%20Chemother5350695073" data-title="In%20vitro%20activity%20of%20piperaquine%2C%20lumefantrine%20and%20dihydroartemisinin%20in%20Kenyan%20Plasmodium%20falciparum%20isolates%20and%20polymorphisms%20in%20Pfcrt%20and%20Pfmdr1." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=In+vitro+activity+of+piperaquine%2C+lumefantrine+and+dihydroartemisinin+in+Kenyan+Plasmodium+falciparum+isolates+and+polymorphisms+in+Pfcrt+and+Pfmdr1.+Mwai+2009" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref36"><span class="order">36. </span><a name="pone.0026005-Basco1" id="pone.0026005-Basco1" class="link-target"></a>Basco LK, Ringwald P (2003) In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob Agents Chemother 47: 1391–1394. <ul class="reflinks"><li><a href="#" data-author="Basco" data-cit="BascoLKRingwaldP2003In%20vitro%20activities%20of%20piperaquine%20and%20other%204-aminoquinolines%20against%20clinical%20isolates%20of%20Plasmodium%20falciparum%20in%20Cameroon.Antimicrob%20Agents%20Chemother4713911394" data-title="In%20vitro%20activities%20of%20piperaquine%20and%20other%204-aminoquinolines%20against%20clinical%20isolates%20of%20Plasmodium%20falciparum%20in%20Cameroon." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=In+vitro+activities+of+piperaquine+and+other+4-aminoquinolines+against+clinical+isolates+of+Plasmodium+falciparum+in+Cameroon.+Basco+2003" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref37"><span class="order">37. </span><a name="pone.0026005-Wong1" id="pone.0026005-Wong1" class="link-target"></a>Wong RP, Lautu D, Tavul L, Hackett SL, Siba P, et al. (2010) In vitro sensitivity of Plasmodium falciparum to conventional and novel antimalarial drugs in Papua New Guinea. Trop Med Int Health 15: 342–349. <ul class="reflinks"><li><a href="#" data-author="Wong" data-cit="WongRPLautuDTavulLHackettSLSibaP2010In%20vitro%20sensitivity%20of%20Plasmodium%20falciparum%20to%20conventional%20and%20novel%20antimalarial%20drugs%20in%20Papua%20New%20Guinea.Trop%20Med%20Int%20Health15342349" data-title="In%20vitro%20sensitivity%20of%20Plasmodium%20falciparum%20to%20conventional%20and%20novel%20antimalarial%20drugs%20in%20Papua%20New%20Guinea." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=In+vitro+sensitivity+of+Plasmodium+falciparum+to+conventional+and+novel+antimalarial+drugs+in+Papua+New+Guinea.+Wong+2010" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref38"><span class="order">38. </span><a name="pone.0026005-Chen1" id="pone.0026005-Chen1" class="link-target"></a>Chen L, Qu FY, Zhou YC (1982) Field observations on the antimalarial piperaquine. Chin Med J (Engl) 95: 281–286. <ul class="reflinks"><li><a href="#" data-author="Chen" data-cit="ChenLQuFYZhouYC1982Field%20observations%20on%20the%20antimalarial%20piperaquine.Chin%20Med%20J%20%28Engl%2995281286" data-title="Field%20observations%20on%20the%20antimalarial%20piperaquine." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Field+observations+on+the+antimalarial+piperaquine.+Chen+1982" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref39"><span class="order">39. </span><a name="pone.0026005-Stepniewska1" id="pone.0026005-Stepniewska1" class="link-target"></a>Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, et al. (2010) In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 201: 570–579. <ul class="reflinks"><li><a href="#" data-author="Stepniewska" data-cit="StepniewskaKAshleyELeeSJAnsteyNBarnesKI2010In%20vivo%20parasitological%20measures%20of%20artemisinin%20susceptibility.J%20Infect%20Dis201570579" data-title="In%20vivo%20parasitological%20measures%20of%20artemisinin%20susceptibility." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=In+vivo+parasitological+measures+of+artemisinin+susceptibility.+Stepniewska+2010" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li><li id="ref40"><span class="order">40. </span><a name="pone.0026005-Dondorp3" id="pone.0026005-Dondorp3" class="link-target"></a>Dondorp A, Nosten F, Stepniewska K, Day N, White N (2005) Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366: 717–725. <ul class="reflinks"><li><a href="#" data-author="Dondorp" data-cit="DondorpANostenFStepniewskaKDayNWhiteN2005Artesunate%20versus%20quinine%20for%20treatment%20of%20severe%20falciparum%20malaria%3A%20a%20randomised%20trial.Lancet366717725" data-title="Artesunate%20versus%20quinine%20for%20treatment%20of%20severe%20falciparum%20malaria%3A%20a%20randomised%20trial." target="_new" title="Go to article in CrossRef"> View Article </a></li><li><a href="http://scholar.google.com/scholar?q=Artesunate+versus+quinine+for+treatment+of+severe+falciparum+malaria%3A+a+randomised+trial.+Dondorp+2005" target="_new" title="Go to article in Google Scholar"> Google Scholar </a></li></ul></li></ol></div> <div class="ref-tooltip"> <div class="ref_tooltip-content"> </div> </div> </div> </div> </div> </section> <aside class="article-aside">  <div class="dload-menu"> <div class="dload-pdf"> <a href="/plosone/article/file?id=10.1371/journal.pone.0026005&type=printable" id="downloadPdf" target="_blank">Download PDF</a> </div> <div data-js-tooltip-hover="trigger" class="dload-hover">  <ul class="dload-xml" data-js-tooltip-hover="target"> <li><a href="/plosone/article/citation?id=10.1371/journal.pone.0026005" id="downloadCitation">Citation</a></li> <li><a href="/plosone/article/file?id=10.1371/journal.pone.0026005&type=manuscript" id="downloadXml">XML</a> </li> </ul> </div> </div> <div class="aside-container"> <div class="print-article" id="printArticle" data-js-tooltip-hover="trigger"> <a href="#" onclick="window.print(); return false;" class="preventDefault" id="printBrowser">Print</a> </div> <div class="share-article" id="shareArticle" data-js-tooltip-hover="trigger"> Share <ul data-js-tooltip-hover="target" class="share-options" id="share-options"> <li><a href="https://www.reddit.com/submit?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0026005" id="shareReddit" target="_blank" title="Submit to Reddit"><img src="/resource/img/icon.reddit.16.png" width="16" height="16" alt="Reddit">Reddit</a></li> <li><a href="https://www.facebook.com/share.php?u=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0026005&t=Declining Responsiveness of Plasmodium falciparum Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast" id="shareFacebook" target="_blank" title="Share on Facebook"><img src="/resource/img/icon.fb.16.png" width="16" height="16" alt="Facebook">Facebook</a></li> <li><a href="https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0026005&title=Declining Responsiveness of Plasmodium falciparum Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast&summary=Checkout this article I found at PLOS" id="shareLinkedIn" target="_blank" title="Add to LinkedIn"><img src="/resource/img/icon.linkedin.16.png" width="16" height="16" alt="LinkedIn">LinkedIn</a></li> <li><a href="https://www.mendeley.com/import/?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0026005" id="shareMendeley" target="_blank" title="Add to Mendeley"><img src="/resource/img/icon.mendeley.16.png" width="16" height="16" alt="Mendeley">Mendeley</a></li> <li><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0026005&text=%23PLOSONE%3A%20Declining Responsiveness of Plasmodium falciparum Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast" target="_blank" title="share on Twitter" id="twitter-share-link"><img src="/resource/img/icon.twtr.16.png" width="16" height="16" alt="Twitter">Twitter</a></li> <li><a href="mailto:?subject=Declining Responsiveness of Plasmodium falciparum Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast&body=I%20thought%20you%20would%20find%20this%20article%20interesting.%20From%20PLOS ONE:%20https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0026005" id="shareEmail" rel="noreferrer" aria-label="Email"><img src="/resource/img/icon.email.16.png" width="16" height="16" alt="Email">Email</a></li> <script src="/resource/js/components/tweet140.js" type="text/javascript"></script> </ul> </div> </div>  <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a aria-label="Check for updates via CrossMark" data-target="crossmark"> <img alt="Check for updates via CrossMark" width="150" src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_BW_horizontal.svg"> </a>  <div class="aside-container collections-aside-container"></div> <div class="skyscraper-container"> <div class="title">Advertisement</div>  <div class='advertisement' id='div-gpt-ad-1458247671871-1' style='width:160px; height:600px;'> <script type='text/javascript'> googletag.cmd.push(function() { googletag.display('div-gpt-ad-1458247671871-1'); }); </script> </div> </div> <div class="subject-areas-container"> <h3>Subject Areas <div id="subjInfo">?</div> <div id="subjInfoText"> <p>For more information about PLOS Subject Areas, click <a href="https://github.com/PLOS/plos-thesaurus/blob/master/README.md" target="_blank" title="Link opens in new window">here</a>.</p> <span class="inline-intro">We want your feedback.</span> Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help! </div> </h3> <ul id="subjectList"> <li> <a class="taxo-term" title="Search for articles about Malarial parasites" href="/plosone/search?filterSubjects=Malarial+parasites&filterJournals=PLoSONE&q=">Malarial parasites</a> <span class="taxo-flag"> </span> <div class="taxo-tooltip" data-categoryname="Malarial parasites"><p class="taxo-explain">Is the Subject Area <strong>"Malarial parasites"</strong> applicable to this article? <button id="noFlag" data-action="remove">Yes</button> <button id="flagIt" value="flagno" data-action="add">No</button></p> <p class="taxo-confirm">Thanks for your feedback.</p> </div> </li> <li> <a class="taxo-term" title="Search for articles about Parasitic diseases" href="/plosone/search?filterSubjects=Parasitic+diseases&filterJournals=PLoSONE&q=">Parasitic diseases</a> <span class="taxo-flag"> </span> <div class="taxo-tooltip" data-categoryname="Parasitic diseases"><p class="taxo-explain">Is the Subject Area <strong>"Parasitic diseases"</strong> applicable to this article? <button id="noFlag" data-action="remove">Yes</button> <button id="flagIt" value="flagno" data-action="add">No</button></p> <p class="taxo-confirm">Thanks for your feedback.</p> </div> </li> <li> <a class="taxo-term" title="Search for articles about Malaria" href="/plosone/search?filterSubjects=Malaria&filterJournals=PLoSONE&q=">Malaria</a> <span class="taxo-flag"> </span> <div class="taxo-tooltip" data-categoryname="Malaria"><p class="taxo-explain">Is the Subject Area <strong>"Malaria"</strong> applicable to this article? <button id="noFlag" data-action="remove">Yes</button> <button id="flagIt" value="flagno" data-action="add">No</button></p> <p class="taxo-confirm">Thanks for your feedback.</p> </div> </li> <li> <a class="taxo-term" title="Search for articles about Parasitemia" href="/plosone/search?filterSubjects=Parasitemia&filterJournals=PLoSONE&q=">Parasitemia</a> <span class="taxo-flag"> </span> <div class="taxo-tooltip" data-categoryname="Parasitemia"><p class="taxo-explain">Is the Subject Area <strong>"Parasitemia"</strong> applicable to this article? <button id="noFlag" data-action="remove">Yes</button> <button id="flagIt" value="flagno" data-action="add">No</button></p> <p class="taxo-confirm">Thanks for your feedback.</p> </div> </li> <li> <a class="taxo-term" title="Search for articles about Medical risk factors" href="/plosone/search?filterSubjects=Medical+risk+factors&filterJournals=PLoSONE&q=">Medical risk factors</a> <span class="taxo-flag"> </span> <div class="taxo-tooltip" data-categoryname="Medical risk factors"><p class="taxo-explain">Is the Subject Area <strong>"Medical risk factors"</strong> applicable to this article? <button id="noFlag" data-action="remove">Yes</button> <button id="flagIt" value="flagno" data-action="add">No</button></p> <p class="taxo-confirm">Thanks for your feedback.</p> </div> </li> <li> <a class="taxo-term" title="Search for articles about Immunity" href="/plosone/search?filterSubjects=Immunity&filterJournals=PLoSONE&q=">Immunity</a> <span class="taxo-flag"> </span> <div class="taxo-tooltip" data-categoryname="Immunity"><p class="taxo-explain">Is the Subject Area <strong>"Immunity"</strong> applicable to this article? <button id="noFlag" data-action="remove">Yes</button> <button id="flagIt" value="flagno" data-action="add">No</button></p> <p class="taxo-confirm">Thanks for your feedback.</p> </div> </li> <li> <a class="taxo-term" title="Search for articles about Plasmodium" href="/plosone/search?filterSubjects=Plasmodium&filterJournals=PLoSONE&q=">Plasmodium</a> <span class="taxo-flag"> </span> <div class="taxo-tooltip" data-categoryname="Plasmodium"><p class="taxo-explain">Is the Subject Area <strong>"Plasmodium"</strong> applicable to this article? <button id="noFlag" data-action="remove">Yes</button> <button id="flagIt" value="flagno" data-action="add">No</button></p> <p class="taxo-confirm">Thanks for your feedback.</p> </div> </li> <li> <a class="taxo-term" title="Search for articles about Artemisinin" href="/plosone/search?filterSubjects=Artemisinin&filterJournals=PLoSONE&q=">Artemisinin</a> <span class="taxo-flag"> </span> <div class="taxo-tooltip" data-categoryname="Artemisinin"><p class="taxo-explain">Is the Subject Area <strong>"Artemisinin"</strong> applicable to this article? <button id="noFlag" data-action="remove">Yes</button> <button id="flagIt" value="flagno" data-action="add">No</button></p> <p class="taxo-confirm">Thanks for your feedback.</p> </div> </li> </ul> </div> <div id="subjectErrors"></div> </aside> </div> </main> <footer id="pageftr"> <div class="row"> <div class="block x-small"> <ul class="nav nav-secondary"> <li class="ftr-header"><a href="https://plos.org/our-journals/">Publications</a></li> <li><a href="/plosbiology/" id="ftr-bio">PLOS Biology</a></li> <li><a href="/climate/" id="ftr-climate">PLOS Climate</a></li> <li><a href="/complexsystems/" id="ftr-complex-systems">PLOS Complex Systems</a></li> <li><a href="/ploscompbiol/" id="ftr-compbio">PLOS Computational Biology</a></li> <li><a href="/digitalhealth/" id="ftr-digitalhealth">PLOS Digital Health</a></li> <li><a href="/plosgenetics/" id="ftr-gen">PLOS Genetics</a></li> <li><a href="/globalpublichealth/" id="ftr-globalpublichealth">PLOS Global Public Health</a></li> </ul> </div> <div class="block x-small"> <ul class="nav nav-secondary"> <li class="ftr-header"> </li> <li><a href="/plosmedicine/" id="ftr-med">PLOS Medicine</a></li> <li><a href="/mentalhealth/" id="ftr-mental-health">PLOS Mental Health</a></li> <li><a href="/plosntds/" id="ftr-ntds">PLOS Neglected Tropical Diseases</a></li> <li><a href="/plosone/" id="ftr-one">PLOS One</a></li> <li><a href="/plospathogens/" id="ftr-path">PLOS Pathogens</a></li> <li><a href="/sustainabilitytransformation/" id="ftr-sustainabilitytransformation">PLOS Sustainability and Transformation</a></li> <li><a href="/water/" id="ftr-water">PLOS Water</a></li> </ul> </div> <div class="block xx-small"> <ul class="nav nav-tertiary"> <li> <a href="https://plos.org" id="ftr-home">Home</a> </li> <li> <a href="https://blogs.plos.org" id="ftr-blog">Blogs</a> </li> <li> <a href="https://collections.plos.org/" id="ftr-collections">Collections</a> </li> <li> <a href="mailto:webmaster@plos.org" id="ftr-feedback">Give feedback</a> </li> <li> <a href="/plosone/lockss-manifest" id="ftr-lockss">LOCKSS</a> </li> </ul> </div> <div class="block xx-small"> <ul class="nav nav-primary"> <li><a href="https://plos.org/privacy-policy" id="ftr-privacy">Privacy Policy</a></li> <li><a href="https://plos.org/terms-of-use" id="ftr-terms">Terms of Use</a></li> <li><a href="https://plos.org/advertise/" id="ftr-advertise">Advertise</a></li> <li><a href="https://plos.org/media-inquiries" id="ftr-media">Media Inquiries</a></li> <li><a href="https://plos.org/contact" id="ftr-contact">Contact</a></li> </ul> </div> </div> <div class="row"> <p> <img src="/resource/img/logo-plos-footer.png" alt="PLOS" class="logo-footer"/> <span class="footer-non-profit-statement">PLOS is a nonprofit 501(c)(3) corporation, #C2354500, based in California, US</span> </p> <div class="block"> </div> </div> <script src="/resource/js/global.js" type="text/javascript"></script> </footer> <script type="text/javascript"> var ArticleData = { doi: '10.1371/journal.pone.0026005', title: '<article-title xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Declining Responsiveness of <italic>Plasmodium falciparum<\/italic> Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast<\/article-title>', date: 'Nov 10, 2011' }; </script> <script src="/resource/js/components/show_onscroll.js" type="text/javascript"></script> <script src="/resource/js/components/pagination.js" type="text/javascript"></script> <script src="/resource/js/vendor/spin.js" type="text/javascript"></script> <script src="/resource/js/pages/article.js" type="text/javascript"></script> <script src="/resource/js/pages/article_references.js" type="text/javascript"></script> <script src="/resource/js/pages/article_sidebar.js" type="text/javascript"></script> <script src="/resource/js/vendor/foundation/foundation.dropdown.js" type="text/javascript"></script> <script src="/resource/js/components/table_open.js" type="text/javascript"></script> <script src="/resource/js/components/figshare.js" type="text/javascript"></script> <script src="/resource/js/vendor/jquery.panzoom.min.js" type="text/javascript"></script> <script src="/resource/js/vendor/jquery.mousewheel.js" type="text/javascript"></script> <script src="/resource/js/components/lightbox.js" type="text/javascript"></script> <script src="/resource/js/pages/article_body.js" type="text/javascript"></script>    <script type="text/x-mathjax-config"> MathJax.Hub.Config({ "HTML-CSS": { scale: 100, availableFonts: ["STIX","TeX"], preferredFont: "STIX", webFont: "STIX-Web", linebreaks: { automatic: false } }, jax: ["input/MathML", "output/HTML-CSS"] }); </script> <script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=MML_HTMLorMML"></script> <div class="reveal-modal-bg"></div> </body> </html>